InTechOpen uses cookies to offer you the best online experience. By continuing to use our site, you agree to our Privacy Policy.

Medicine » Oncology » "Evolution of the Molecular Biology of Brain Tumors and the Therapeutic Implications", book edited by Terry Lichtor, ISBN 978-953-51-0989-1, Published: February 27, 2013 under CC BY 3.0 license. © The Author(s).

Chapter 14

Mechanisms of Aggressiveness in Glioblastoma: Prognostic and Potential Therapeutic Insights

By Céline S. Gonçalves, Tatiana Lourenço, Ana Xavier-Magalhães, Marta Pojo and Bruno M. Costa
DOI: 10.5772/52361

Article top


                            Common genetic alterations in GBM affect the RB, p53 and RTKs pathways. The aberrant deregulation of these pathways in GBM leads to alterations in cell cycle, migration, proliferation, angiogenesis, and apoptosis. Known proto-oncogenes or growth-promoting genes (shown in green), such as EGFR, PIK3CA (p110α) and AKT, are activated by mutations, overexpression and amplification, while tumor suppressor genes (show in red), such as PTEN, Arf and p53, are lost or inactivated by mutations, deletions, loss of heterozigosity, and epigenetic changes.
Figure 2 Common genetic alterations in GBM affect the RB, p53 and RTKs pathways. The aberrant deregulation of these pathways in GBM leads to alterations in cell cycle, migration, proliferation, angiogenesis, and apoptosis. Known proto-oncogenes or growth-promoting genes (shown in green), such as EGFR, PIK3CA (p110α) and AKT, are activated by mutations, overexpression and amplification, while tumor suppressor genes (show in red), such as PTEN, Arf and p53, are lost or inactivated by mutations, deletions, loss of heterozigosity, and epigenetic changes.

Mechanisms of Aggressiveness in Glioblastoma: Prognostic and Potential Therapeutic Insights

Céline S. Gonçalves1, 2, Tatiana Lourenço1, 2, Ana Xavier-Magalhães1, 2, Marta Pojo1, 2 and Bruno M. Costa1, 2

1. Introduction

1.1. Glioblastoma

Glioblastoma (GBM) is the most prevalent and most malignant (WHO grade IV) type of brain tumor in adults [1, 2]. In the United States, there are ~10,000 new cases diagnosed annually, and >50,000 patients living with the disease [2, 3]. The clinical responses of patients are particularly poor and vary greatly among individuals [4], and ~32% of all diagnosed cases survive less than a year [3]. This highly aggressive tumor develops either de novo (primary GBM), or as the result of the malignant progression from a lower-grade glioma (secondary GBM). In both cases, prognosis is very poor, and the median survival when radiotherapy and chemotherapy are combined is approximately 15 months [5]. Importantly, GBM is also characterized by extensive heterogeneity at the cellular and molecular levels. These tumors are highly diffuse, with extensive dissemination of tumor cells within the brain, which hinders complete surgical resection. These aggressive characteristics are associated with a remarkable resistance to therapies available today [6], which unfortunately are mostly palliative. In the context of their highest incidence of all malignant brain tumors in adults, their highly aggressive behavior and therapy-insensitive nature, which together account for a very poor prognosis of GBM patients, this chapter will focus specifically on GBM. In particular, it will review the different hypotheses of glioma/GBM-initiating cells, the major alterations at the levels of gene expression and signaling pathways found in GBM, as well as putative biomarkers of GBM prognosis, and current therapies currently available or under investigation for dealing with these tumors.


Figure 1.

Schematic representation of the differentiation process of neural stem cells into different cell lineages of the CNS and putative cells of origin of gliomas. Protein markers for neural stem cells, progenitors cells, and differentiated cells are indicated in boxes. The normal differentiation process (green arrows) originates three main types of cells in the mature CNS, including neurons and glial cells (particularly oligodendrocytes and astrocytes; ependymal cells are not represented). The most classical hypothesis on the origin of glioma cells is represented by orange arrows (differentiated glial cells are malignantly transformed through a dedifferentiation process). The most recent hypothesis postulating that gliomas originate from the direct transformation of neural stem cells or glial progenitor cells is represented by grey arrows.

1.2. Glioma/GBM-Initiating cells

The true cellular origin of gliomas, including GBM, is still a debatable question. It is generally accepted that identifying such tumor-initiating cells may allow a better understanding of tumor biology, and ultimately help in designing improved therapies for GBM. All human tumors arise from a series of molecular alterations that occur in a small number, or even single, founder cells. These tumor cells present a clonal nature due to the sequential accumulation of multiple rare genetic and epigenetic events. The critical importance of the tumor microenvironment in influencing tumor cells behavior and evolution has been recently recognized [7]. Indeed, the tumor microenvironment has been associated with the generation and maintenance of tumor heterogeneity; thus, understanding not only the surrounding microenvironment but also tumor heterogeneity, as well as their relationships, may be crucial in understanding the biology of these tumors. In the case of the brain tissue, a highly complex microenvironment with extreme phenotypic and functional diversity, the multiplicity of putative brain tumor cells of origin, and the variety of niches in which the malignant cells may evolve, is even more challenging. Thus, understanding this complexity is crucial to provide firm evidence for the cellular origin of gliomas [8-10]. Two different hypotheses for the origin of glioma cells, or tumor cells in general, have been proposed (Figure 1), as detailed below.

One classical hypothesis postulates that cancer cells arise from the accumulation of alterations that occur in differentiated mature cells (glial cells in the case of glioma tumors, including GBM), which would result in a dedifferentiation of these cells along the carcinogenic process. This concept is supported, for instance, by the histological similarities between functional and differentiated glial cells and tumor cells from gliomas. In addition, before the experimental identification of the adult neural stem cells (NSCs), glial cells were the only known replication-competent population of cells in the adult brain, which further supported the idea that highly-proliferative glioma cells could derive from accumulated alterations in differentiated and proliferative glial cells. A landmark study supporting this theory showed that differentiated cells could be transformed into a pluripotent embryonic stem cell phenotype by using a cocktail of transcription factors [11]. However, this hypothesis has never been adequately tested, as there have been experimental limitations that preclude its validation, including: (i) the absence of good mature “astrocyte” markers in in vivo experiments [12], as it is now well known that the commonly used astrocyte marker GFAP is also expressed by adult NSCs; (ii) in vitro, the culture of mature astrocytes is particularly difficult; (iii) culturing astrocytes from neonatal mouse cortex has been described to contain also immature progenitor cells [13].

The second and most recent hypothesis assumes that cancer cells arise from the accumulation of alterations that occur directly in stem cells, or progenitor (multipotent) undifferentiated cells, that are present in different tissues throughout the entire lifetime (neural stem cells or glial progenitor cells in the case of brain gliomas). According to this rationale, the tumorigenic process would not be accompanied by a dedifferentiation mechanism, as the molecular alterations would accumulate directly in undifferentiated cells [7-9, 14]. In support of this hypothesis is the concept of cancer stem cells (CSCs), which is a subpopulation of cells in the tumor that displays self-renewal capacity, and which can give rise to heterogeneous cancer cells that constitute the tumor. However, it should be noted that the concepts of CSCs and tumor-initiating cells have been frequently confused. The term ‘‘tumor-initiating cells’’ refers to the cells of origin of the tumor, whose alterations support tumor establishment and progression; in contrast, CSCs would more accurately be referred to as tumor-propagating cells, with stem cell-like properties, which are not necessarily the cells of origin [8, 14, 15]. A study by Chen and colleagues (2010) may help to distinguish these different cell populations and their role on tumor development, particularly in GBM [16]. They demonstrated a hierarchical organization of brain tumor-initiating cells by identifying subpopulations of clonal and long-term proliferating cells in GBM specimens. These subpopulations were shown to be hierarchically organized and to give rise to tumors with different molecular and histopathological features [16]. There are specific and very well delimited regions in the brain where neural stem cells and progenitor cells exist, particularly the subventricular zone (SVZ) of the fore brain lateral ventricles, and the subgranular zone (SGZ) in the dentate gyrus of the hippocampus [8-10]. It has been hypothesized that these are favorable regions where the process of gliomagenesis may originate, as these regions present an attractive microenvironment that has been described as propitious for the growth of stem cells, namely in the SVZ [8-10]. There is increasing experimental evidence that the SVZ is one of the most important regions of origin for malignant gliomas [10] as it may present ideal conditions for gliomagenesis, like the exposure to a transcription factor cocktail ideal for their growth. When compared to any other brain regions, stem cell-containing compartments have been shown to be more susceptible to tumor transformation [10], which additionally may argue in favor of this hypothesis of tumors arising from changes in stem/progenitor cells. Additionally, while it may be coincidence, there is a great similarity between the SVZ stem/progenitor cells and glioma cells. For instance, malignant astrocytic tumors in the brain typically appear close to the lateral ventricles [9, 10].

In the recent years, the notable therapy resistance of gliomas, namely GBM, has been associated with the presence of glioma stem cells (GSCs). These cells present characteristics of stem cells, including: (i) self-renewal; (ii) multipotency, i.e., the capacity to differentiate into other cell lineages; and (iii) high replicative potential. GSCs are predicted to be difficult to target by anti-cancer therapeutics because they have a slow cell cycle, present high levels of proteins involved in drug efflux, and do not express or are dependent on particular oncoproteins for which targeted therapies are currently available [17]. GSCs were one of the first types of cancer stem cells isolated from solid tumors [18]. It was shown that as few as 100 GSCs could give rise to tumors that recapitulated the parental tumor when implanted in xenografted immunodeficient mice, whereas as many as 1,000,000 non-GSCs could not [18]. This suggests that neoplastic clones are maintained exclusively by a little fraction of cells with stem cell properties [18]. Of note, studies involving the use of GSCs face many difficulties, particularly in isolating such cells directly from biopsies, partly because of the high cellular heterogeneity composition of the specimen. On the other hand, currently there are no standardized methods available for cell sorting and assessment of “stemness” [8]. Indeed, there is a relevant discussion regarding the best methodology for culturing GSCs isolated from human GBM specimens. It has been argued by several authors that adherent monolayer cultures of glioma cells allow a more homogeneous exposure to the culture conditions (e.g., nutrients and oxygen levels) than nonadherent cultures, thus increasing the homogeneity of the cell population, reviewed in [8]. In contrast, the sphere-forming assay has been widely used for this purpose. The fidelity and benefits of these assays are still under debate. Thus, there is an exigency to standardize methods for identifying and isolating GSCs with unequivocal markers. It is believed that the use of NSCs markers is a good principle for identifying GSCs, as NSCs are now known to exist in very restricted areas of the brain, and can be unambiguously identified with specific markers [8]. Indeed, in the last decade, putative markers of GSCs have been identified, including Nestin, CD133, L1CAM, CD15, CD44, Id1, and integrin-α6 [8, 10, 14, 19-21]. Nonetheless, none of these markers is sufficient to, independently, identify specifically GSCs, implicating that a functional identification of GSCs (including their ability to (i) be tumorigenic in in vivo models, (ii) form neurospheres in culture; (iii) be multipotent) is still mandatory.

2. Gene expression and signaling in GBM

GBM, like other cancers, is a disease that presents several alterations, including DNA mutations, copy number aberrations, and chromosomal rearrangements, but also DNA and histones epigenetic modifications, ultimately resulting in alterations in the gene expression profiles [22]. Molecular studies from the last decades have identified critical genetic alterations that affect many key pathways involved in the regulation of typical cancer hallmarks, such as alterations in cell cycle, migration, proliferation, survival, angiogenesis, invasion and apoptosis [22]. While several alterations in signaling pathways occur in GBM, such as Wnt, Notch and Shh pathways (particularly relevant due to their associations with cancer stem-cells and resistance to radiochemotherapy) [23, 24], the most frequent aberrations in GBM occur in three critical signaling pathways: (i) retinoblastoma (RB), (ii) p53, and (iii) RTK/RAS/PI3K pathways [22, 25, 26], as detailed in Figure 2 and below.

2.1. Retinoblastoma (RB) pathway

Mutations in genes implicated in cell cycle regulation that allow cells to proliferate uncontrollably have been frequently identified in GBM, as in other human tumors [26-28]. The RB pathway, which is important in the G1/S transition, is aberrantly inactivated in GBM through the alteration of several genes and proteins [28].

In a normal condition, the RB protein (encoded by RB1 gene, the first tumor suppressor gene described), a negative regulator of the cell cycle, is recruited to specific promoters through its interactions with E2F transcription factors. RB inhibits the transcription of genes by directly suppressing the transactivating function of E2F, and by recruiting factors that mediate transcriptional repression [27, 28]. E2F regulates the promoters’ activity of several genes related to (i) cell cycle, such as Cyclin E (CCNE) and A (CCNA), (ii) DNA replication, such as minichromosome maintenance complex component 7 (MCM7) and cell division cycle 6 (CDC6), (iii) nucleotide byosynthesis, such as ribonucleotide reductase (RRM), (iv) mitotic progression, such as Cyclin B1 (CCNB1) and cyclin-dependent kinase 1 (CDK1), and (v) apoptosis activation, such as apoptotic peptidase activating factor 1 (APAF-1) and caspases, such as caspase 3 (CASP3) [27, 28]. The interaction between RB and E2F can be disrupted due to the phosphorylation of the RB protein by Cdk4/6 kinases [27, 28]. To be active, these kinases are dependent of Cyclin proteins, namely CCND2 that competes for the binding site with Ink4 proteins [27]. Thus, the function of Ink4 is to prevent the formation of the active kinase complex (CCND2/Cdk4/6) [27]. This process is ultimately regulated by external signals, such as growth factors, which induce the cell to progress to the S phase [27].

In GBM, the RB1 gene is frequently mutated [26]. However, the loss of function of RB is also reported to be a consequence of the amplification of CDK4 and CDK6, as well as by the inactivation of the INK4A/B (isoforms of CDKN2A/B) and INK4C (encoded by CDKN2C), which are inhibitors of Cdk4/6 [26]. Ultimately, these alterations lead to E2F accumulation and the consequent progression to S phase mediated by E2F-target genes [26, 27].

2.2. p53 Pathway

The TP53 gene encodes a protein (p53) that also controls the cell cycle by regulating target genes involved in cell cycle arrest, apoptosis and senescence [27]. Moreover, p53 has been named as the “guardian of the genome” because it leads to the arrest of cells with DNA damage in G1 phase, in order to promote DNA repair processes [29]. On the other hand, if irreparable genetic injuries occur, p53 induces cell death by activating the apoptotic machinery [29]. In normal unstressed cycling cells, some proteins, such as the ubiquitin ligase Mdm2, bind to p53 to promote its degradation via the ubiquitin/proteasome pathway [29-31]. The p53-mediated upregulation of MDM2 gene leads to a negative feedback that will maintain the levels of p53 very low in these cells [30, 31]. In this context, p53 loss of function may lead, for example, to uncontrolled growth and increased genetic instability. Its loss of function may be due to several reasons, including: (i) inactivating mutation [26], (ii) amplification of MDM2 and MDM4 [26, 31], and (iii) loss of function of ARF product encoded by CDKN2A, which interacts with and sequesters Mdm2 [26, 31, 32]. Unlike Mdm2, which degrades p53, Mdm4 inhibits p53 by binding to its transcriptional activation domain [31]. Moreover, Mdm4 also inhibits the degradation of Mdm2 [31].


Figure 2

Common genetic alterations in GBM affect the RB, p53 and RTKs pathways. The aberrant deregulation of these pathways in GBM leads to alterations in cell cycle, migration, proliferation, angiogenesis, and apoptosis. Known proto-oncogenes or growth-promoting genes (shown in green), such as EGFR, PIK3CA (p110α) and AKT, are activated by mutations, overexpression and amplification, while tumor suppressor genes (show in red), such as PTEN, Arf and p53, are lost or inactivated by mutations, deletions, loss of heterozigosity, and epigenetic changes.

2.3. Receptor Tyrosine Kinase (RTK) pathways

GBM cells also commonly present a constitutive activation of cell growth signaling pathways by the overexpression of several mitogens and their specific membrane receptors [22, 24, 26, 33]. Glioma cells can also acquire mutations in the membrane receptors becoming independent of exogenous growth stimulation, increasing survival and motility [22, 24, 26, 33, 34]. In GBM, the deregulation of growth factor signaling occurs frequently by the amplification and/or activating mutations of RTKs [22, 26]. These play critical roles in several cellular processes, including cell growth, motility, survival and proliferation, and are tightly controlled by various physiological mechanisms (e.g., autocrine loops in which RTK ligands are produced in result of receptor activation) [26]. One of the most described RTK alteration in GBM is the deletion of exons 2-7 of epidermal growth factor receptor (EGFR) gene that results in the loss of the extracellular domain (EGFR-vIII mutant) [26]. Notwithstanding, other genetic alterations affecting EGFR, such as amplifications, activating point mutations that affect the extracellular domain, and other deletions in the region coding for the cytoplasmic domain, have also been described [26]. Moreover, alterations of other RTKs also occurs frequently in GBM, including: (i) overexpression of platelet-derived growth factor receptor (PDGFR) and its ligands PDGFA and PDGFB, suggesting an autocrine or paracrine loop activation, (ii) activating mutations in ERBB2 (member of the EGFR family), and (iii) activating mutations in hepatocyte growth factor receptor (MET) [22, 26, 33, 34]. RTKs mediate its functions by downstream effectors, namely phosphatidylinositol 3-kinase (PI3K), mitogen-activated protein kinase (MAPK) and signal transducer and activator of transcription (STAT) signaling cascades [34]. Although genetic alterations in RTKs may potentially activate these pathways, they can also be specifically activated due to other aberrations. Among them, the PI3K pathway is the most described in GBM and is involved in cell growth, proliferation, differentiation, motility and survival [26, 34]. The most frequent alterations involve inactivating mutations and homozygous deletions of PTEN [26]. This gene encodes the enzyme phosphatidylinositol (3,4,5)-trisphosphate 3-phosphatase, which removes a phosphate from phosphatidylinositol-(3,4,5)-triphosphate (PIP3), converting it to phosphatidylinositol-(4,5)-bisphosphate (PIP2) [22]. Thus, PTEN counteracts the action of the PI3K, which catalyzes the addition of a phosphate to PIP2 at the 3 position, converting it to PIP3 [22]. The accumulation of PIP3 recruits Akt to the plasma membrane. Here, Akt is activated by phosphorylation, promoting cell survival and proliferation [22]. The PI3K enzymatic complex is formed by 2 subunits, one regulatory protein (p85α), encoded by PIK3R1, and one catalytic protein (p110α), encoded by PIK3CA [22]. Note that other variants of this complex exist, but the referred subunits are the most expressed in GBM and the most widely-studied. Activating missense mutations and in-frame deletions have been detected in the PIK3CA [26]. One deletion was identified in the adaptor binding domain, raising the hypothesis that it may disrupt the normal interaction between p110α and its regulatory subunit, p85α [26]. Interestingly, in a few percentage of samples without activating mutations in the catalytic subunit, inactivating mutations were detected in the regulatory subunit [26]. This suggests a functional redundancy of these mutations as they individually activate PI3K. Again, the amplification of AKT3 gene, which encodes one of the Akt proteins, was described recently in a small fraction of GBM samples [26]. Other known mutation that ultimately leads to activation of PI3K and MAPK is the activating mutation of RAS [26]. RAS is indirectly activated by RTKs through the dissociation of a GDP molecule and association to a GTP. However, in a normal condition, this activation is quickly reverted from RAS-GTP to RAS-GDP. This RAS mutation impedes the dissociation of GTP, remaining RAS constitutively active. Neurofibromin 1 (NF1), which negatively regulates RAS signaling, is also downregulated in GBM by NF1 mutations or deletions, resulting in increased RAS signaling. Moreover, loss of expression of NF1 without evidence of genomic alteration was also observed [26]. In addition to its critical effects in cell growth, motility, and survival, the PI3K pathway seems to be also important in the activation of HOX genes, which were recently described to be important for the malignant phenotype of GBMs [35-37] (see section 3.3 for details).

2.4. Crosstalk between RB, p53, and RTK pathways in GBM

The development of new platforms of genome-scale screenings has allowed a more robust identification of the accumulation of genetic and epigenetic alterations. The Cancer Genome Atlas (TCGA) project, for example, was established with the aim of using genome-wide analysis technologies, which include DNA copy number, gene expression, DNA methylation, and nucleotide sequencing, to understand the molecular basis of cancer [26]. With this multiplatform profiling and using an integrative analysis, they identified a highly interconnected network of aberrations in GBM that include the pathways described above (RB, p53, RTKs and PI3K pathways) [26]. Interestingly, this integrative analysis showed a statistical tendency to mutual exclusivity for the specific alterations of components within each pathway. Nonetheless a great percentage of samples harbored aberrations in all signaling pathways [26], which is in agreement with the hypothesis that these pathways are a core prerequisite for GBM disease.

2.5. Other key alterations in GBM

In addition to the most common genetic alterations found in GBM, several other aberrations have been described. For example, mutations in IDH1 and IDH2 genes, which encode the metabolic enzymes isocitrate dehydrogenases were described. These reports suggest that these mutations lead to a new pro-oncogenic activity of IDH1/2 with the production of R(-)-2-hydroxyglutarate, an onco-metabolite [38, 39] (see section 3.2 for details). Other classes of proteins extremely important in GBM are DNA repair proteins, as they increase the probability of mutations. In fact, at least one of the MMR genes (MLH1, MSH2, MSH6 or PMS2) is mutated in hypermutated GBM samples [26], decreasing DNA repair competencies in these cells.

2.6. Molecular subclasses of GBM

Using an unsupervised hierarchical clustering analysis, Verhaak et al. [40] used TCGA data to successfully classify GBM into four subtypes - classical, mesenchymal, proneural and neural - improving and validating previous classifications of GBM [37, 41-47].

The identity of the classical subtype was defined by displaying the most common genomic aberrations of GBM, with 93% of samples presenting amplifications in chromosome 7 paired with loss of chromosome 10, 95% showing high levels of EGFR amplification and/or expression, and EGFR-vIII activating point mutations. These amplifications of EGFR co-occurred with focal homozygous deletions targeting CDKN2A, which in turn was almost mutually exclusive with other alterations in RB pathway components, such as RB1, CDK4 and CCDN2. However, this subtype does not present TP53 mutations. Additionally, the Notch (NOTCH3, JAG1, LFNG) and Sonic hedgehog (SMO, GAS1, GLI2) signaling pathways, as well as the neural precursor and stem cell marker NES, were highly expressed in this subtype [40].

The mesenchymal subtype presents a focal hemizygous deletions of 17q11.2 region that contains the NF1 gene. In fact, this deletion was associated with lower expression of NF1 in most cases. However, NF1 was also found to be mutated predominantly in this subtype, and sometimes this mutation co-occurred with PTEN inactivating mutations. Moreover, TRADD, RELB and TNFRSF1A genes, belonging to the tumor necrosis factor (TNF) superfamily, and genes encoding proteins from the NF-ĸB pathways, are highly expressed. Additionally, mesenchymal markers, such as CHI3L1 and MET, were expressed [40].

The most relevant features of the proneural subtype were high levels of PDGFRA gene expression in combination with its focal amplification, and point mutations in IDH1. Importantly, these aberrations seem to be mutually exclusive. Loss of heterozygosity and inactivating mutations of TP53 were frequent in this subtype. While less frequent than in classical GBM samples, half of proneural samples also manifested amplification in chromosome 7, paired with loss of chromosome 10. PIK3CA and PIK3R1 activating and inactivating mutations, respectively, were observed mostly in samples without PDGFRA aberrations. Oligodendrocytic development genes, such as PDGFRA, NKX2-2 and OLIG2, were highly expressed. Lower expression of CDKN1A was observed, probably due to OLIG2 overexpression, which was described to be able to downregulate CDKN1A. Additionally, this subtype also presents the expression of proneural developmental genes, such as SOX genes, as well as DCX, DLL3, ASCL1 and TCF4 [40].

In what concerns the neural subtype, few characteristics were reported, and it was almost merely classified based on neuron markers expression, including neurofilament light chain polypeptide (NEFL), gamma-aminobutyric acid A receptor (GABRA1), synaptotagmin I (STY1), and solute carrier family 12 (SLC12A5) [40].

3. Molecular prognostic factors of GBM

It is widely recognized that the molecular stratification of GBM patients may prove crucial in rationalizing treatment decisions, for which a set of molecular markers predictive of tumor response to specific therapies and/or patient outcome are required. The most well established prognostic factors in GBM patients include age, general performance status, tumor histological features and the extent of tumor resection [48]. Recently, several studies have identified biological and molecular features of GBMs that present prognostic value [37, 46, 49-58] and may help in therapeutic decisions. The work performed so far presents reasons for both optimism and caution regarding the improvements in the diagnosis and treatment of patients, but also demand validation in prospectively followed and in uniformly treated patients. Therefore, the focus remains in the identification of biomarkers that truly foster patient distinction in ways that may improve therapeutic decisions. The current most relevant prognostic biomarkers for GBM are summarized in Table 1, of which the most promising are briefly discussed below.

Molecular Prognostic Marker References
MGMT promoter methylation[52]
IDH1 and IDH2 mutations[57]
Loss of chromosome 10[56]
Activation of the PI3K/AKT pathway [50, 58]
HOX genes signature[36, 37]
HOXA9 overexpression[35, 36]
CHI3L1 (YKL40) expression[53, 56]
miRNA expression signatures[59]
EGFR expression[37]
EGFR mutation (EGFR-vIII)[51, 55]
PTEN expression (wild-type)[55]
Molecular signatures[40, 46]
High expression of angiogenic genes[46]
Stem-cell like gene expression signatures[37, 49, 54]
Activation of MAPK members[58]
PTEN and DLL3 expression[46]

Table 1.

Selected molecular prognostic markers for glioblastoma.

3.1. MGMT promoter methylation

Many studies have shown that the methylation status of MGMT (O6-methylguanine-DNA methyltransferase) gene is currently one of the most promising biomarkers of prognosis in GBM patients, although it has not yet reached broad clinical applicability [52, 60]. MGMT encodes a DNA-repair protein that removes alkyl groups from the O6 position of guanine, an important site for DNA alkylation. When DNA is left unrepaired, the lesions induced by chemotherapy trigger apoptosis and cytotoxicity [61]. Hegi and co-workers [52] showed that the epigenetic silencing of MGMT by promoter methylation leads to the loss of MGMT expression and reduced DNA-repair activity, resulting in increased sensitivity of the tumor cells to temozolomide (TMZ) treatment. In fact, they reported that this increased sensitivity is translated into differences in patient survival, as the methylation of the MGMT promoter is associated with longer overall survival (OS) in patients with GBM. Indeed, patients whose MGMT promoter is methylated and are treated with TMZ have an increased OS (median of 21.7 months), as well as a higher 2-year survival rate (46%), in comparison to patients treated with TMZ but with unmethylated MGMT promoter (median survival of 12.7 months and 2-year survival of 13.8%), suggesting that GBM patients whose tumors present MGMT expression do not benefit from TMZ treatment [52]. These results suggest MGMT promoter methylation as an independent and favorable predictive factor to patients’ response to TMZ therapy [52]. Despite these remarkable findings suggesting MGMT as a prognostic biomarker and as a specific predictor of response to TMZ-based chemotherapy, there is still a significant body of controversy surrounding them. Such controversy is mainly due to the heterogeneity of the patients enrolled in the study groups, as they present different glioma histologies, grades and treatment regimens, as well as the fact that different studies analyzed MGMT at different levels, including mRNA expression, methylation status and protein levels (as summarized in [62]). In an attempt to replicate Hegi’s findings, Costa and co-workers [62] analyzed a set of 90 GBM patients treated with postoperative TMZ-based chemoradiation regarding MGMT methylation. Despite a trend for longer overall and progression-free survival in GBM patients with MGMT promoter methylation, the differences did not reach statistical significance [62]. Moreover, sample classification as methylated or unmethylated for a certain gene is still controversial, as the relationship between the overall CpG island methylation, CpG methylation at individual sites, and their effects on gene silencing, is highly dependent on the location within the gene [63]. In this sense, Bady and co-workers [64] evaluated the relationship between the specific location of CpG methylation, MGMT expression and the outcome of patient in a population homogenously treated with alkylating agents. They reported two regions of methylated CpG’s that present strong association with patient longer survival, which negatively correlate with MGMT gene expression [64]. This is consistent with MGMT expression silencing via CpG methylation, resulting in sensitization to alkylating agents [64]. Similarly, Shah and colleagues also identified three regions of methylated CpGs on MGMT, associated with favorable patient progression-free survival, within a population of 44 GBM patients treated with radiotherapy and concomitant and adjuvant TMZ [65]. Nonetheless, the value of MGMT methylation status is also supported by a recent clinical trial that compares radiotherapy and TMZ treatment in elder patients, and reported an association between MGMT methylation and good outcome in the TMZ cohort, but not in the radiotherapy cohort [66]. Similarly, a meta-analysis performed by Olson and co-workers [67] that included 2018 patients from 20 different studies, showed that the silencing of MGMT was highly associated with improved OS in patients receiving chemotherapy as a part of the adjuvant treatment, a mild association in patients that received adjuvant radiotherapy, and no benefit in those submitted to surgery alone.

3.2. IDH1 and IDH2 mutations

Other important prognostic factors for GBM have been revealed by recent genomic studies and concern the presence of mutations in isocitrate dehydrogenase 1 and 2 genes (IDH1 and IDH2; IDH when referring to both) [26, 57, 68]. These are NADP-dependent enzymes that catalyze the oxidative decarboxylation of isocitrate to α-ketoglutarate, with the simultaneous production of NADPH [69]. The high-throughput sequencing of GBM revealed that IDH1 mutations occur in 12% of GBM, are somatic and heterozygous, and a consequence of the change of a guanine to an adenine at position 395 of the IDH1 gene (G395A), leading to the replacement of an arginine with a histidine at amino acid residue 132 of the protein (R132H) [57]. Similarly, sequence evaluation of IDH2 exons revealed a mutation in a histidine at amino acid residue 172 (R172), which is the exact analogue of the R132 residue in IDH1 [68]. Overexpression of IDH1 R132H reduces the formation of α-ketoglutarate and increases the levels of HIF-1α [70]. As stated above, a recent study suggested that mutant IDH1 reduces α-ketoglutarate to R(-)-2-hydroxyglutarate, while converting NADPH to NADP+ [38, 39]. Even though the mechanism is yet to be clarified, it seems probable that the increased capacity to produce 2-hydroxyglutarate of cells presenting IDH1 R132H mutation contributes to tumorigenesis [38]. IDH mutations are highly frequent in secondary GBM (up to 80%), but are rare in primary GBM (less than 10%) [68, 71]. IDH mutations are correlated with younger age at diagnosis, and with GBM patients’ longer survival when compared to patients with IDH wt genes [68, 72]. Mutations in IDH1 and IDH2 are mutually exclusive, which indicates that they might independently confer a growth advantage to mutated cells [73]. Moreover, IDH mutations generally associate with specific genetic and clinical characteristics when compared to gliomas that have IDH wt. In particular, it was shown that IDH mutations and amplification of EGFR in GBM are mutually exclusive events [74], and that the methylation of the MGMT gene promoter is often associated with IDH mutations [74, 75]. However, this association is yet to be clarified as it may represent a direct consequence of the activity of the mutant IDH, or an alternative marker for epigenetic changes in tumors presenting IDH mutations (reviewed in [76]). So, the deep understanding of the link between IDH mutations and common genetic events in GBM might furnish insights into their roles on gliomagenesis [40, 68]. Furthermore, a recent study evaluated the response of a series of 86 secondary GBM to TMZ treatment, and correlated several markers of GBM (including IDH mutations, 1p19q co-deletion, MGMT promoter methylation status, and TP53 expression) with progression-free survival and OS [77]. This study showed that IDH mutations were present in 73.4% of the analyzed patients, and that these mutations were associated with higher progression-free survival [77]. The authors also evaluated the response of patients presenting IDH mutations and MGMT promoter methylation, and found that patients presenting this combination had the best response to TMZ treatment, reporting also that IDH mutations seems to be a significant marker for positive chemosensitivity in secondary GBM [77].

3.3. Molecular subclasses and prognostic value

Strikingly, as stated above, mutations in IDH1 have been included in a GBM signature that allowed the division of GBMs into subtypes according to their recurrent genomic alterations [40] (see section 2.6 for details). The importance in the division of GBM into subtypes lies on the possible application of different therapeutic approaches, as treatments efficacy differs per subtype [40]. Aggressive therapy significantly delayed mortality in classical and mesenchymal subtypes, and a tendency to longer outcome was observed for the neural subtype, yet patients whose GBM present proneural features, associated with younger age, do not seem to benefit from highly aggressive therapies although presenting longer survival [40]. In this sense, some of the genetic events underlying the different GBM subtypes could become part of the clinical routine to rationalize therapeutic decisions, and ultimately lead to more personalized therapies for groups of patients with GBM.

3.4. HOX genes signature

Recent evidences have been revealing a remarkable resemblance between tumorigenic and developmental processes, indicating the relevance of molecular regulatory mechanisms crucial on normal development and on the tumorigenic process. Homeobox (HB) genes encode transcription factors that primarily play a crucial role during normal development, and are divided into two classes: class I comprises clustered homeobox (HOX) genes, and class II includes non-HOX genes, which are dispersed through the genome, and mainly serve as cofactors for HOX proteins [78]. During embryonic development, HOX genes are sequentially expressed from 3’ to 5’ along the anterior-posterior axis contributing to the temporospatial development of limbs and organs [79]. The mechanisms underlying HOX genes control in normal development occur according to three main principles: spatial collinearity, posterior prevalence, and temporal collinearity [80]. These were found to be altered in cancer as a consequence of three major mechanisms proposed by Abate-Shen [81]: temporospatial deregulation, gene dominance and epigenetic regulation. Different groups have been reporting the deregulation of these mechanisms in different HOX genes, and in different tumors (reviewed in [80]).

The aberrant expression of HOX genes have been reported as crucial in several hallmarks of cancer, including increased proliferation, angiogenesis and invasion, and apoptosis resistance in leukemia and in several solid tumors [80, 82-85]. Interestingly, in recent years, HOX genes aberrant expression has been implicated in gliomagenesis. Abdel-Fattah and co-workers [86] evaluated the expression of all HOX genes in primary astrocytomas and in non-tumor brain specimens, reporting that some HOX genes are abnormally expressed in malignant astrocytomas. A subsequent report by Murat et al. [37] identified a HOX-dominated gene cluster, suggestive of a signature that displays srm cell-like self-renewal properties. These authors argue show that the expression of HOXA10 gene in GBM neurospheres is consistent with a role of HOX genes in glioma stem-like cell compartments [37]. Interestingly, the HOX-dominated gene signature arises along malignant progression to GBM, and is an independent predictive factor of chemo-radiotherapy resistance in patients [37]. Later, Costa and co-workers [35] showed that HOXA genes are predominantly activated in GBM, as compared to lower-grade gliomas and normal brain tissue, suggesting they may be a useful component of a molecular classification of gliomas. By analyzing expression microarrays data from 100 GBMs, they identified tumors with abnormal chromosomal domains of transcriptional activation, which comprise the HOXA cluster, and is reversibly regulated by the PI3K pathway [35]. Of all HOXA genes, HOXA9 expression was predictive of worse GBM patient outcome, and associated with pro-proliferative and anti-apoptotic functions, which may explain the unfavorable prognosis of GBM patients with HOXA9 reactivation [35]. More recently, Gaspar et al. [36], showed pediatric GBM cell lines that are resistant to TMZ present the coordinated expression of several HOX genes, of which HOXA9 and HOXA10 were highlighted as crucial effectors in this resistance [36]. In line with Costa et al. [35] report, Gaspar suggested that the HOX-enriched signature is regulated by the PI3K pathway, and interestingly, is associated with resistance to TMZ in pediatric GBM cell lines [36]. Moreover, pediatric patients with high-grade gliomas that express HOXA9 and HOXA10 presented shorter survival [36].

3.5. CHI3L1 (YKL40) expression

The molecular prognostic biomarkers currently available require the evaluation of tumor tissue in order to assess gene expression and promoter methylation levels. Moreover, tumor progression and treatment responses are monitored using imaging techniques, which do not distinguish the effects of treatment and tumor regrowth. In fact, patients who are submitted to magnetic resonance imaging (MRI) shortly after radiotherapy show increased volume of the tumor, which in up to 50% of the cases, is a consequence of the increased blood vessel permeability due to radiotherapy, an effect called pseudoprogession [87]. As it is difficult to distinguish between the therapeutic effects and real growth of the tumor [88], in addition to the impossibility of multiple tumor sampling during the course of the malignancy [89, 90], demand the establishment of less invasive prognostic and predictive markers. Serum markers that correlate with tumor biological properties might prove crucial in providing prognostic information and response to treatment, therefore allowing the proper adjustment of therapeutics, and improve care of patients with GBM. A study conducted by Tanwar [91] analyzed gene expression microarray data of tumor tissue from glioma patients, and showed that chitinase 3-like 1 (CHI3L1 or YKL40) was the most highly expressed among 10000 genes, when comparing to normal brain tissue [91]. The function of YKL-40 in gliomas and other tumors is yet to be fully clarified; however, it is thought to be involved in increased cell proliferation, differentiation, angiogenesis, decreased apoptosis, and extracellular matrix remodeling [92-94]. Interestingly, YKL-40 is secreted both by tumor cells and by tumor-associated macrophages in the bloodstream, therefore allowing its quantification in the blood. YKL-40 was found to be increased in the serum of patients with several solid tumor types, as breast, colorectal, ovary, small cell lung cancer and GBM (reviewed in [93]). Particularly in GBM, YKL-40 serum concentrations seem to be a strong predictor of an aggressive phenotype [53, 91], as the increased expression of YKL-40 appears to be associated with glioma grade, resistance to radiotherapy, shorter time to progression, and worse patient OS [53, 95-97]. However, to establish YKL-40 serum levels as a prognostic marker, there is still the need to perform further prospective studies that concern repeated determinations of YKL-40 levels before and after surgery. As YKL-40 can be reproducibly measured in the serum, and this biomarker is already well established for routine use, its inclusion in the clinical practice should be relatively straightforward, and might provide crucial information on tumor progression.

In conclusion, the identification of molecular biomarkers that truly aid in the distinction of patients and therapeutic decisions still requires much effort. The integration of clinical and molecular data is becoming more frequent, and easier to perform and analyze, which will probably lead to more targeted and effective treatments. Moreover, it seems probable that sets of molecular biomarkers for GBM will be established in the next few years, and will become part of the clinical routine, leading to tailored therapies for subgroups of GBM patients. Importantly, the timely identification of patients who are not likely to respond to a certain therapy would allow their integration in clinical trials with novel therapies, but also to avoid the possible adverse side effects of a therapy that may not prove beneficial. Equally interesting, the establishment of molecular biomarkers of tumor therapy resistance may lead to a more guided and rational design of novel therapeutic agents and clinical trials for GBM patients. In the search for GBM patient individualized therapy, the discovery of particular tumor molecular features, as the status of MGMT promoter methylation status, the mutation status of IDH1 and IDH2, the expression of HOXA genes, and the serum levels of YKL-40, may prove crucial as initial building blocks of a panel of molecular biomarkers that may have real clinical implications. The challenge ahead is to discover further molecular markers of GBM, but also to integrate all the knowledge in an interdisciplinary way, considering different GBM subtypes, which altogether might allow a more rational and efficient fight against GBM.

4. New molecular targets and treatments

As described throughout this chapter, the molecular and cellular heterogeneity of GBM represents a major therapeutic challenge, but also offers a large number of opportunities to specific targeting of tumor cells’ alterations. Furthermore, the unsatisfactory prognosis of GBM patients, independently of the used treatment approaches, and the absence of a cure or significant advances in the treatment of GBM, are the major drivers of GBM therapeutics research.

4.1. Classic therapeutics

The current standard therapy for the treatment of GBM includes maximal surgical resection, followed by radiotherapy (RT) with concomitant and adjuvant administration of alkylating agents [98]. Administration of RT is usually given after the surgical removal of the tumor in order to eliminate residual tumor cells [99]. Alkylating agents act by introducing methyl groups in different positions in the DNA, resulting in DNA damage and specific cytotoxicity, that ultimately leads to apoptosis and cell death [100]. Before 1999, only nitrosourea-based chemotherapeutics were approved for the treatment of GBM, which includes oral lomustine (CCNU) and intravenous carmustine (BCNU) [101]. In 1999, FDA approved Gliadel® that consists in a polymeric biodegradable wafer that is able to release carmustine during 2-3 weeks after implantation in the gap where the tumor was removed during surgery [101-103]. Furthermore, in this same year, FDA granted accelerated approval to the imidazole derivative of the second-generation class of alkylating agents, TMZ, mainly because of its efficient absorption after oral administration and its ability to easily cross the blood-brain barrier [101, 104].

TMZ was regularly approved by the FDA in 2005, and became the standard chemotherapeutic agent for the treatment of GBM [5]. The approval of TMZ was mainly due to the improvement in the OS of patients observed in a landmark study by Stupp et al. [5]. This clinical trial involving 573 patients with newly diagnosed GBM showed an increase in OS from 12.1 months to 14.6 months when patients were treated with RT plus TMZ comparing with RT alone [5]. In 2009, the 5-years retrospective analysis from this phase III clinical trial reported that, in addition to the improvement in OS, the 5-year survival rate was also higher in the group of patients treated with RT and TMZ, showing again the benefits of this treatment [105]. Nevertheless, some molecular mechanisms of resistance to this agent were identified, like the methylation status of the MGMT gene, which encodes a protein that repairs the damage induced by TMZ, and alkylating agents in general, resulting in chemoresistance [106].

Besides TMZ, bevacizumab (BVZ, also known as Avastin®) was also conceded accelerated approval by the FDA in 2009 as monotherapy for patients with progressive GBM that did not respond to standard care (TMZ + RT) [101, 107]. This drug is a monoclonal antibody that targets VEGF, which is involved in the formation of new blood vessels [99]. Since GBM are highly vascularized tumors, this drug presented an attractive way to target tumor-associated increased angiogenesis [108]. When BVZ was combined with TMZ + RT for the treatment of newly diagnosed GBM patients in a phase II clinical trial, an improvement in OS (19.6 vs. 14.6 months) and progression-free survival (PFS, 13.6 vs. 6.9 months) was reported, when compared to the control cohort of the European Organization for Research and Treatment of Cancer-National Cancer Institute of Canada (EORTC/NCIC), in which patients were treated only with RT and TMZ [109]. BVZ also showed good radiographic responses in patients with recurrent GBM (71% and 35%, according to Levin and Macdonald criteria, respectively) when used first as a single agent, and later combined with irinotecan (topoisomerase I inhibitor) in a phase II clinical trial [110]. Although some exciting clinical results were described, several in vitro and in vivo studies have been unmasking unpredictable consequences of BVZ treatment. The treatment of intracranial xenograft mouse models of GBM with this VEGF inhibitor showed a decrease in the vascular network and contrast enhancement in MRI, but also a 68% increase in the infiltration of tumor cells trough the brain parenchyma [111, 112]. Furthermore, BVZ treatment increased the hypoxic microenvironment which is also implicated in increased invasion ability of tumor cells [24, 112].

4.2. Novel molecular targeted therapeutics

Conceptually, the development of targeted therapies for the treatment of GBM represents a significant advance in the search for a cure for this devastating disease. First, the specificity of these therapies has the potential to reduce toxic side effects. Second, the direct blockade of altered oncogenic signaling cascades may allow the reduction of tumor cell proliferation [113]. This next part will review some of the most promising therapeutic molecular and targeting strategies, including membrane proteins and growth factor receptors (e.g. RTK), and intracellular signaling pathways.

4.2.1. Therapeutic targeting of membrane protein/growth factor receptors

RTKs represent attractive targets for this therapeutic approach, since they are associated with GBM oncogenesis, and the binding of growth factors to these receptors activate signaling pathways that drive GBM cells survival and proliferation [113, 114] (see section 2.3 for information). There are two kinds of inhibitors for RTKs: (i) inhibitors targeting the intracellular tyrosine kinase domain (TKD), and (ii) monoclonal antibodies that can block RTK activation or target the RTK-expressing cells [115].

  1. EGFR

As stated above, EGFR amplification, overexpression and mutation are frequent events in GBM cells and increased EGFR signaling is known to increase tumor proliferation, invasion ability, angiogenesis and blocking apoptosis [22, 116]. Several small molecule inhibitors targeting EGFR have been developed and approved for the treatment of particular cancers, as erlotinib and gefitinib in the treatment of advanced metastatic non-small cell lung cancer [24, 117]. This RTK can be targeted with a large number of inhibitors, like lapatinib (EGFR2, ErbB2), vandetanib (EGFR, VEGFR-2), PF-00299804 (EGFR, ERBB2 and ERBB4), BIBW2992 (EGFR, ERBB2, ERBB4), AEE 788 (EGFR, ERBB2, VEGFR), and monoclonal antibodies, as cetuximab (EGFR) and nimotuzumab (EGFR) [98, 116]; however, this section focus on the most reviewed and clinically tested drugs for the treatment of GBM (erlotinib, gefitinib and cetuximab). Erlotinib and gefitinib although, extensively tested in clinical trials for GBM patients (either already completed or currently ongoing), have not shown a significant benefit, and thus failed to reach clinical applicability (Table 2) [118]. The chimerical monoclonal antibody cetuximab (Erbitux) can also inhibit EGFR, and was shown to inhibit the mutant EGFR-vIII in glioma cells [119, 120]. Furthermore, preclinical studies using GBM xenograft models suggest that cetuximab could be effective for the treatment of invasive GBM [121]. The clinical evaluation of the administration of cetuximab in phase II trials for recurrent GBM patients has shown mixed results. The combination of cetuximab with BVZ and irinotecan resulted in 5% complete responses (CR), 21% partial responses (PR) and 40% of the patients with stable disease (SD), with only 9% of the GBM patients presenting signs of progressive disease (PD); the 6 months progression-free survival (6-PFS) of 33% obtained in this trial was also surprising [108]. In another phase II clinical trial for recurrent GBM patients, treatment with cetuximab showed worse outcomes, with a median time-to-progression (TTP) of only 1.9 months, and only 7.3% of the patients being progression free at 6 months after treatment [122].

Most of the EGFR amplified GBMs also present expression of the mutant EGFR-vIII [116]. Since this mutated form of EGFR is absent in normal tissues, an immunotherapy-based approach to target EGFR-vIII was developed and is now under clinical trials (phase I, II and III) [118, 123]. This vaccine, called rindopepimut (CDX-110, PEPvIII) consists in a 14 aminoacids peptide that specifically recognizes EGFR-vIII, combined with an immunoadjuvant (keyhole limpet hemocyanin), that will potentiate an immune response against EGFR-vIII-positive tumor cells [124]. The clinical applicability of this vaccine was already tested in different clinical trials showing the benefits of this strategy (Table 2). Newly diagnosed GBM EGFR-vIII positive had a significant improvement in OS from 15.2 months (treated with TMZ + RT) to 23.2 months (CDX-110 + granulocyte macrophage-colony stimulating factor, GM-CSF, and TMZ, after RT), consistent with the benefit of this vaccine alone in other studies (OS 26 months vs. 15 months) [124, 125].

  1. PDGFR

As referred previously, PDGFR is also frequently overexpressed in GBM [114]. As described for other RTK, PDGFR can also be blocked with different pharmacological inhibitors, such as imatinib mesylate (PDGFR, c-KIT, BCR-ABL), sunitinib (PDGFR, VEGFR, c-KIT), sorafenib (PDGFR, VEGFR, RAF), tandutinib (PDGFR, FLT3, c-KIT), vatalanib (PDGFR, VEGFR, c-KIT), IMC3G3 (PDGRFα), pazopanib (PDGFR, c-KIT, EGFR) or dasatinib (PDGFRβ, Src, BCR/Abl, c-KIT, ephrin A2) [98, 116]. However, this part will focus on the best characterized PDGFR inhibitor, imatinib mesylate (Gleevec or Livec), already evaluated in phase I/II clinical trials with GBM patients, which was originally FDA approved for the treatment of acute myeloid leukemia [106, 126]. In vitro treatments of GBM cells with imatinib have already shown inhibitory effects on cell proliferation, as a result of cell cycle arrest, increase apoptotic population and decreased clonogenic ability [127]. Its administration in mice models of GBM also showed an improvement in survival [128]. In clinical studies, imatinib mesylate was usually combined with hydroxyurea (HU), a ribonucleotide reductase inhibitor that blocks DNA synthesis [126, 129]. Treatment of recurrent GBM in phase II clinical trials was mostly disappointing, with 6-months PFS (6-PFS) of only 3% and 16% [130, 131]. Combination with HU, although showing a mild increase in OS and 6-PFS rates, again showed a lack of efficacy as compared to RT + TMZ [126]. The best result using imatinib was achieved in a phase I clinical trial for recurrent malignant glioma (MG), where imatinib was combined with HU and vatalanib (VEGFR inhibitor), with 24% of GBM patients revealing a radiographic partial response, 49% showing signals of stable disease, however 27% of the patients had progressive disease [132] (Table 2).

  1. VEGFR

The therapeutic targeting of GBM-associated angiogenesis is already an approved strategy through VEGF inhibition with BVZ, but can also be achieved through inhibition of VEGF receptors using specific inhibitors, like cediranib, sorafenib, sunitinib, pazopanib, vandetanib, CT-332 (all VEGFR), XL-184 (VEGFR2, Met, RET, c-KIT, Flt3, Tie-2), semaxanib or AEE 788 [98, 116, 133]. For instance, cediranib (AZD2171) inhibits all VEGFR subtypes and was explored in phase I, II and III clinical trials [116]. The outcomes of cediranib (AZD2171) treatment in GBM patients are described as similar to the ones observed for BVZ, although only one of the completed trials has published results (Table 2) [116]. As reported for BVZ, also cediranib was associated with infiltrative cells not visible with contrast-enhanced MRI [112, 134]. In orthotopic mouse models of GBM, this VEGFR inhibitor induced alterations in the permeability and diameter of blood vessels, alleviating edema and increasing the survival of the mice [135].

  1. Met

Met is an RTK for hepatocyte growth factor (HGF) that activates a series of signaling pathways, as referred above in section 2.3, similar to what is observed for EGFR or PDGFR activation, which ultimately leads to proliferative and invasive behaviors of cancer cells [106, 136]. In a series of 62 GBM patient samples, Met was found to be overexpressed and associated with poor prognosis, and with an invasive phenotype, supported by invasive multifoci lesions and expression of metalloproteinases 2 and 9 [137]. Inhibitors targeting Met include tivantinib, and cabozantinib (XL184) a potent inhibitor of several kinases, cabozantinib (XL184), which hase shown significant inhibitory effect on GBM tumor growth [138]. Furthermore, three phase I and II clinical trials for the evaluation of cabozantinib on the treatment of newly diagnosed GBM (monotherapy or combined with RT + TMZ) and recurrent GBM (monotherapy) (NCT00960492, NCT00704288 and NCT01068782) are now ongoing [118]. Another therapeutic approach to target HGF/Met axis is the use of the monoclonal antibody against HGF, rilotumumab (AMG-102), which was already tested during a phase II [116] clinical trial for recurrent GBM (Table 2); a second phase II trial to test the combination of rilotumumab with Avastin in patients with recurrent MG is now recruiting patients (NCT01113398) [118].

  1. Integrins

Therapeutic targeting of the cell adhesion receptors integrins, which are transmembrane glycoproteins that attach cells to extracellular matrix proteins of the basement membrane or to ligands on other cells, have also proved to be a valuable therapeutic strategy for the treatment of GBM, with several recent clinical trials testing the success of the integrin inhibitor cilengetide (EMD 121974) as a monotherapy or in combination with RT + TMZ (Table 2) [139]. Cilengitide is an RGD (Asp-Gly-Asp) synthetic peptide that inhibits integrins αVβ3 and αVβ5 by receptor binding competition [139]. In vitro studies have shown an anti-angiogenic effect of this inhibitor by inhibiting proliferation and differentiation of endothelial progenitor cells, without affecting apoptosis [140]. In GBM cells, cilengitide exerted only a moderate loss of viability and was unable to sensitize GBM cells to radiotherapy and TMZ treatment [141]. Clinical studies with this drug have shown limited toxicity, but also reduced beneficial effect, when administered in newly diagnosed patients of GBM with RT+ TMZ (Table 2).

4.2.2. Therapeutic targeting of intracellular signaling pathways

  1. PI3K/AKT/mTOR pathway

As already mentioned the PI3K/Akt/mTOR pathway represents one of the most altered pathways in cancer, including GBM [113, 116]. Several inhibitors targeting different elements of this pathway are available and being tested both pre-clinically and at the clinical level. Enzastaurin is a specific inhibitor of protein kinase C (PKC) proteins, thus indirectly inhibiting Akt [104, 113, 142]. In preclinical studies, this inhibitor was able to suppress proliferation of GBM cells and tumor growth in GBM xenograft mice models [143]. In clinical studies, especially for recurrent GBM patients this drug failed to improve patient outcome, with PFS, OS and 6-PFS inferior to that of patients treated with lomustine in phase III clinical trials (Table 2) [144]. Inhibition of Akt can also be achieved using perifosine (KRX-0401), which affects the interaction of PIP3 with the PH domain of Akt [24]. When this drug was compared to mTOR inhibition in in vivo models with differential expression of PTEN, the treatment with perifosine did not alter tumor volume; on the other hand, treatment with mTOR inhibitor resulted in decrease tumor volume [145]. Furthermore, only a clinical trial phase II for patients with recurrent MG is under evaluation and no results are available until now (NCT00590954) [118]. A HIV type I (HIV-1) protease inhibitor called nelfinavir with applications in HIV infections is also able to downregulate Akt, and was proposed as an Akt inhibitor [146, 147]. Preclinical studies showed that treating GBM cells and xenograft mouse models with nelfinavir is able to sensitize tumor cells to RT and TMZ treatment [148]. Furthermore, this protease inhibitor decreases VEGF levels and angiogenesis, as well as HIF-1 expression levels and can cause endoplasmic reticulum stress and autophagy [146, 149]. Three phase I clinical trials to assess the toxicity of this treatment combined with RT + TMZ in newly diagnosed GBM are currently recruiting patients or active and ongoing (NCT01020292, NCT00694837, NCT00915694) [118].

Several inhibitors of PI3K are also available, but the clinical evaluation of their efficacy is still very preliminary [150]. The class of pan-PI3K inhibitors (inhibit the catalytic p110 subunit) include LY294002, ZSTK474, and wortmannin. Derivatives of LY294002 and wortmannin, include SF1126 (LY294002 conjugated with an RGD peptide), PWT-458 and PX-866 (the first is a PEGylated derivate of wortmannin and the second is a wortmannin analog) [150]. From this group of specific PI3K inhibitors, only evaluation of PX-866 is proposed in a phase II clinical trial for the treatment of recurrent GBM patients, and is currently recruiting patients (NCT01259869) (Table 2) [118]. XL147 and GDC-0941 are also class I PI3K inhibitors, and IC877114 (targets p110δ) and TG100-115 (targets p110δ and p110γ) are PI3K isoform-specific inhibitors [150]. In turn, LY294002 was able to potentiate the citotoxicity of TMZ in glioma cells [151, 152]. Besides these agents that only target PI3K there are several dual PI3K/mTOR inhibitors, as PI-103, PI-540, PI-620, XL765, BEZ235 and BGT226 [150]. XL765 and XL147 were already tested in a phase I clinical trial with recurrent GBM patients (Table 2). Some preclinical studies support the theory of targeting these pathways in GBM therapeutics. Combination of LY294002 with the mTOR inhibitor rapamycin (or sirolimus) was able to diminish the self-renewal capacity of GBM cells and induce differentiation of cancer stem cell like cells (CSC); the same effect was achieved using a dual PI3K/mTOR inhibitor, NVP-BEZ235, which additionally reduced the ability of GBM CSLC to form tumors in vivo [153].

For specific targeting of mTOR, several inhibitors were developed and tested clinically, like sirolimus (rapamycin), everolimus (RAD001) and temsirolimus (CCI-779) [106, 133]. All of these agents were already evaluated for the treatment of GBM in phase I and II clinical trials, but no significant improvements were seen (Table 2). A preclinical study showed that the outcome of mTOR inhibitory treatments could be efficiently monitored by Positron Emission Tomography (PET) based only in glucose and thymidine metabolism, through the uptake of [18F]FDG and [18F]FLT [154]. Furthermore, combination with other kinase inhibitors like AEE788 (inhibits both EGFR and VEGFR2) also showed some preclinical promising results, since its combination with everolimus (RAD001) resulted in increased effect on cell cycle arrest, proliferation and apoptosis, and impact tumor growth and survival in vivo [155]. This combination was tested in a phase I/II trial in 2006 for the treatment of recurrent GBM (NCT00107237) [118]. One liability of these therapies is that they only target mTORC1, and although this is the best characterized mTOR isoform, it is also known that full activation of PI3K/AKT pathway also requires mTORC2 [156]. Consequently, it is argued that dual inhibition of mTOR complexes 1 and 2 will be more efficient [156]. Preclinical studies have shown a significant decrease in tumor volume and growth in xenograft mouse models of GBM treated with PI3K/mTOR inhibitor AZD8055 [157]. Furthermore, there are three phase I clinical trials recruiting patients with MG (drug/trial reference: AZD8055/NCT01316809; CC-223/NCT01177397; OSI-027/NCT00698243) to test this possibility [118].

  1. RAS/RAF/MEK/ERK/MAPK pathway

Another important pathway contributing to the neoplastic process is the one mediated by RAS/RAF/MEK/MAPK [106]. Inhibitors targeting members of this pathway include the farnesil transferase inhibitors of RAS, such as tipifarnib (Zanestra or R115777) and lonafarnib (Sarasar or SCH 66336) or multiple kinases inhibitors that target this pathway, like sorafenib [98, 116]. Some of the more significant clinical results of tipifarnib are summarized in Table 2. A phase I clinical trial to test the effectiveness of combining tipifarnib with TMZ and RT for newly diagnosed GBM or gliosarcoma is now ongoing (NCT00049387) [118]. Sorafenib is described as an inhibitor of EGFR, PDGFR and RAF, that can block MEK activation and, in preclinical studies, was able to induce apoptosis, and decreased proliferation of GBM cells [98, 158]. At the clinical level, it has been extensively studied in 12 clinical trials with completed, ongoing or recruiting status [118]; however, the results have still been somewhat different, with good results for newly diagnosed GBM and recurrent GBM, but when combined with BVZ for the treatment of recurrent GBM, it failed to improve survival, showing a high percentage of patients with progressive disease (Table 2) [118].

  1. Histone deacetylases (HDACs)

Epigenetic events are crucial during the carcinogenic process, in which the chromatin state and remodeling are important mediators. Histone deacetylases (HDAC) are responsible for chromatin condensation and repression of transcription [159, 160]. Mechanistically they catalyze the elimination of acetyl groups from lysine residues in N-terminal tails of histone proteins [161]. The use of specific HDAC inhibitors has been described as an attractive opportunity to alter cancer-related epigenetic modifications [159]. These inhibitors are also reported as being able to block angiogenesis and invasion, promote cell cycle arrest and apoptosis, and to act as immunomodulators [116, 159, 160]. Valproic acid (VPA) is a short chain fatty acid, class I and IIa HDAC inhibitor, used as an anticonvulsant drug and frequently administered to treat glioma-associated seizures [159, 162, 163]. So, when the results of the EORTC/NCIC TMZ trial were analyzed taking in consideration the anti-epileptic drugs used, an interesting result showing a benefit in OS of the patients treated with TMZ + RT that were under VPA treatment was observed, suggesting that this drug could enhance the effects of TMZ + RT treatment [162]. VPA in combination with TMZ in vitro showed an increase in TMZ cytotoxicity, even for TMZ resistant cell lines, through downregulation of MGMT [164-166]; in vivo, this combination had also a benefit in tumor growth inhibition [164]; and increased the effects of γ-radiation in glioma cells [165]. Clinically, the evaluation of VPA for the treatment of GBM is proposed in two clinical trials: a phase II trial to evaluate the efficacy of VPA + RT followed by combination of VPA + BVZ for the treatment of children with high-grade gliomas (HGG) (NCT00879437) and a phase II trial to test the combination of VPA with TMZ and RT in adult HGG (NCT00302159) [118]. Vorinostat is also an inhibitor of class I and II HDACs, tested in several clinical trials now recruiting patients (NCT01378481, NCT01266031, NCT00731731, NCT01110876, NCT00555399) [118, 163]. The results of some of the already completed clinical trials for HDAC inhibitors as GBM therapeutics are in some way disappointing, with no radiographic responses observed when recurrent GBM patients treated with romidepsin and vorinostat failing to improve survival outcomes in different combinatory strategies (Table 2).

Drug; Target(s) Clinical Trials/Population/Results Refs
Phase I, and II clinical trials
Acceptable toxicity and tolerable treatment with daily administrations of 150-200 mg/day dose
Newly diagnosed GBM: combined with TMZ showed a PFS of 7.2 months and OS of 15.3 months; worse outcome for patients older than 70 years old; combined with standard care (RT + TMZ), the OS was 19.3 months, and correlated with MGMT promoter methylation and PTEN expression; combinations with other drugs are also under clinical trials (BVZ, administration after TMZ + RT, RT and erlotinib in younger patients) (NCT00124657, NCT00720356).
Recurrent GBM: erlotinib as a single agent was not able to improve PFS compared to standard treatment (TMZ or carmustine + RT); combined with mTOR inhibitor sirolimus, treatment was well tolerated and OS was 33.8 weeks; combination with carboplatin showed a 30 weeks OS;
Recurrent MG: combination with BVZ resulted in partial or total radiographic response for 48% of GBM patients and association with PFS; GBM tumors showing high levels of HIF-2α and VEGFR2 expression presented a worst prognosis.
Recruiting or ongoing clinical trials combining erlotinib with isotretinoin, sirolimus and vorinostat, and also single agent administration for patients harboring the EGFR-vIII mutation (NCT01110876, NCT01103375, NCT01257594, NCT00509431).
Nonprogressive GBM: as single agent, 1-year PFS was only 9% and less than 53% of 2 months, and less than 57% of the patients were alive after 1 year.
[118, 167-175]
(Iressa or ZD1839);
Phase I, and II clinical trials
Recurrent GBM: as single agent, the treatment was well tolerated and resulted in OS of 39.4 weeks and PFS of 8.1 weeks. In a phase II study, OS did not overcome 8.8 months.
Newly diagnosed GBM: 1-year OS (54.2%) and 1-year PFS (16.7%) were not significantly different from controls of other clinical trials.
(CDX-110, PEP-3);
Phase I, II, and III clinical trials
EGFR-vIII-positive newly diagnosed GBM: given with GM-CSF, TTP of 14.2 months (vs. 6.3 months of historical controls) and OS of 26 months (vs. 15 months of historical controls); administration with TMZ also improved TTP (15.2 months vs. 6.4 months) and OS (23.2 months vs. 15.2 months); phase III trial (recruiting status) is projected to test the efficacy of rindopepimut with TMZ (NCT01480479).
Newly diagnosed GBM: TTP was 10.2 months and OS was 22.8 months (vaccine given with DC);
Phase II clinical trial is recruiting patients with relapsed GBM EGFR-vIII positive to test the efficacy of rindopepimut with BVZ (NCT01498328).
[118, 124]
Imatinib mesylate;
Phase I, II, and III clinical trials
Newly diagnosed GBM: a phase II study with 20 patients showed a OS of 6.2 months.
Recurrent GBM or MG: as single agent was well tolerated until doses of 800-1200 g/day, but very poor outcome with 6-PFS of 3%, only 2/34 patients with PR, and 6/34 with SD; when combined with HU, 6-PFS (27%) improved, but still very poor; combination with HU and vatalanib was well tolerated and resulted in OS of 48 weeks, PFS of 12 weeks and 6-PFS of 25%. In another phase II study the outcome of patients treated with imatinib as single agent was also (in newly diagnosed GBM) very poor (6-PFS: 16%); when combined with HU, imatinib also lacked efficacy.
A phase III clinical trial showed no differences in TMZ resistant GBM patients treated with imatinbib + HU or HU alone (NCT00154375); phase II clinical trials combining imatinib with HU and Zactima were also performed but no results have been published (NCT00613054).
[118, 126, 129-132, 179, 180]
Cediranib (AZD2171);
Phase I, II, and III clinical trials
Recurrent GBM: as a single agent showed a PFS was 117 days and OS was 227 days (phase II); phase I trials to test cediranib + lomustine to treat GBM is already completed but without published results (NCT00503204); a phase III trial with the same combinatory approach for the treatment of recurrent GBM in currently ongoing (NCT00777153); recruiting trials include combination with gefitinib (NCT01310855) and with cilengitide (NCT00979862).
Newly diagnosed GBM: all clinical trials are currently ongoing or recruiting – phase I and phase I/II cediranib + RT + TMZ (NCT01062425 and NCT00662506); phase I combination with BVZ (NCT00458731); phase I combination with gamma secretase inhibitor RO4929097 (NCT0130855).
[118, 181, 182]
Rilotumumab (AMG-102);
Phase II clinical trial
Recurrent GBM: when combined with prior BVZ treatment, did not affect PFS (4-4.1 weeks vs. 4.1-4.7 weeks), but OS was significantly different (3.4-3.6 months vs. 10.9-11.4 months).
Phase I, and II clinical trials
Completed a phase I clinical study in patients with solid tumors (NCT00726583); Recruiting recurrent GBM patients for a phase II clinical trial (NCT01259869).
Phase I clinical trial
Recurrent GBM: combination with a PI3K inhibitor XL147 already completed phase I trial (NCT0124460).
Recruiting for a phase I trial for combination with TMZ to treat MG (NCT00704080).
PKCβ (indirect
inhibition of Akt)
Phase I, II, and III clinical trials
Recurrent or progressive MG: in recurrent HGG, monotherapy had no significant impact in 6-PFS (7%); when compared with lomustine in a phase III clinical trial, no improvement in OS or PFS was achieved.
[118, 142, 144, 184, 185]
Phase I, and II clinical trials
Phase I clinical trials showed that everolimus was well tolerated even when combined with RT + TMZ, BVZ or erlotinib. Changes in metabolism detected with FDG positron emission tomography days after administration of everolimus.

Newly diagnosed GBM: combination with TMZ + RT + BVZ followed by BVZ + everolimus in a phase II clinical trial resulted in 57% PR, 1 CR, 18-months OS of 44%, and 18-months PFS of 29%.
Phase I, and II clinical trials
Phase I trial showed that temsirolimus combined with TMZ and RT increased the risk of infectious diseases (3/25 fatal infections).
Recurrent GBM: it was well tolerated as a single agent, and 36% radiographic responses were observed; 6-PFS was 7.8%, and OS was 4.4 months (phase II).
[189, 190]
Phase I, and II clinical trials
Recurrent GBM or MG: in tumors without PTEN, mTOR inhibition correlated with decreased proliferation of the tumors (phase I/II); combination with erlotinib (phase II) resulted in 47% SD, no CR or PR and 6-PFS of 3.1%; phase I/II trial combinatory treatment with erlotinib is currently ongoing (NCT00509431); phase I trial is recruiting patients to test combinatory treatment with vandetanib (NCT00821080).
Recruiting patients with solid tumors to test combination with a vaccine (NCT01522820).
[118, 172, 191]
(Zarnestra, R115777);
Phase I, and II clinical trials
Newly diagnosed GBM: combined with RT and with or without TMZ, this treatment was well tolerated until doses of 300 mg (4-week cycle) (phase I). Administration with RT well tolerated until 200 mg/day, OS of 12 months and 1/9 PR, 4/9 SD, and 3/9 rapid progression. No significant improvement in survival with tipifarnib before RT (OS of 7.7 months).
Recurrent GBM: treatment well tolerated, but 6-PFS (11.9%) and PFS (8 weeks) very poor, although one GBM patient remained progression-free for 36 months.
Phase I, and II clinical trials
Newly diagnosed GBM: combination of TMZ and sorafenib after RT + TMZ showed 13% PR, 53% SD, and 28% PD. OS was 12 months, 1-year PFS was 16%, and PFS was 6 months (phase II); also tested in combination with erlotinib/tipifarnib/temsirolimus (NCT00335764).
Recurrent GBM: combination with TMZ resulted in OS of 41.5 weeks, 1-year OS of 34.4%, PFS of 6.4 weeks (6-PFS: 9.4%); 3% of the patients had PR, 4.7% SD, and 50% PD (phase II); combination with BVZ was also tested (NCT00621686).
Ongoing or recruiting clinical trials: NCT00734526 (phase I/II: sorafenib + RT + TMZ for the treatment of newly diagnosed GBM), NCT00884416 (phase I single agent HGG), NCT00329719 (phase I/II: combination with temsirolimus for recurrent GBM).
[118, 196, 197]
(EMD 121974);
Phase I, II, and III clinical trials
Well tolerated until doses of 2400 mg/m2
Newly diagnosed GBM: when combined with RT + TMZ, the OS was 16.1 months and patients with MGMT promoter methylation tend to show a higher PFS and OS; clinical trials testing the efficacy of cilengitide with TMZ + RT in patients with or without MGMT methylation are now recruiting or ongoing (NCT00813943, NCT0068922).
Recurrent GBM: as a single agent no complete responses were observed, but median OS was at least 6.5-9.9 months.
[118, 198-200]
Phase I, and II clinical trials
Progressive or recurrent GBM/MG: combination with bortezomib in a phase II trial resulted in very poor results (6-PFS 0%, OS 3.2 months, TTP 1.5 months); phase II monotherapy showed a 6-PFS of 15.2%, TTP of 1.9 months, PFS of 11.2 months, and OS of 5.7 months;
Ongoing trials: phase I/II combination with BVZ and TMZ for recurrent MG (NCT00939991), phase I combination with TMZ for MG (NCT00268385), phase I combination with BVZ and irinotecan for recurrent GBM (NCT00762255).
[118, 201, 202]
Phase II clinical trial
Recurrent MG: no radiographic responses, 72% PD and 28% SD; 6-PFS of 3%, PFS of 8 weeks, and OS of 34 weeks; 83% of the patients stopped treatment due to tumor progression, and 11% due to treatment toxicity.
PFS (median Progression-Free Survival); OS (median Overall Survival); TTP (median Time-to-Progression); PR (Partial Response); SD (Stable Disease); PD (Progressive Disease); 6-PFS (6 month PFS); BVZ (Bevacizumab); RT (Radiotherapy); TMZ (Temozolomide); GM-GSF (granulocyte macrophage-colony stimulating factor); DC (Dendritic Cells); HU (Hydroxyurea); MG (Malignant Glioma); HGG (High Grade Glioma).

Table 2.

Examples of clinical trials with molecularly targeted therapies directed to the most commonly altered signalling pathways in GBM.

4.3. Novel therapeutic approaches

As stated above, a small population of cells within the tumor, called cancer stem-cells, presents self-renewal capacity, ability to differentiate and initiate tumorigenesis, and express several markers of neural stem cells [24, 33, 116]. Furthermore, these cells are increasingly recognized as a niche of radiochemotherapy-resistant cells, making then attractive targets for new therapies [24, 49, 204]. There are several signaling pathways altered in cancer stem cells and that represent possible targets, such as PI3K, OLIG2, Shh, Wnt and Notch signaling pathways [24, 116].

Another novel therapeutic strategy to treat cancer-related diseases is gene therapy (GT). GT was proposed for a long time as a molecular strategy that may help circumvent the non-specific cytotoxicity of the current pharmacological inhibitors, through specific delivery of suicide, pro-apoptotic, TP53, and other genes to tumor cells that, ultimately, lead to cancer regression or cure [106, 205]. GT can be performed delivering conditional or toxic transgenes using viral or non-viral delivery systems, including exosomes and stem cells [205, 206]. In GBM, the delivery of the thymidine kinase (TK) gene, produced by the herpes simplex virus type 1 (HSV1), in combination with the prodrug ganciclovir (GCV), using both retrovirus and adenovirus, was already tested at clinical level. The advantage of using retroviruses to deliver viral vectors is the specificity, since they target only highly proliferating cells. On the other hand, adenoviruses infect both quiescent cells and rapidly dividing cells [207]. A retroviralmediated delivery was already applied to newly diagnosed GBM patients until phase III clinical trial, but it was rejected after failing to improve survival compared to RT + TMZ [208]. Another promising strategy is the combination of viral vectors with factors that stimulate the immune system, as, for example, the delivery of the suicide gene HSV1 TK gene, with the cytokine IL-2. This strategy was already tested in 12 patients with recurrent GBM, where it was proved to be safe and well tolerable [209]. However, in terms of outcome, there were no patients with complete response and the PFS and OS were only 4.5 and 7.5 months, respectively [209].

The induction of an immune response against tumor cells, called immunotherapy, is also a novel approach for the treatment of cancer, including GBM [210]. Immunotherapy can be performed with two different approaches: increasing the immune response to the tumor (active immunotherapy) with long term immunization, or delivering immune effectors to an immediate immune response (passive immunotherapy) [106]. Potent anti-tumor immunity is achieved through antigen-presenting cells, of which dendritic cells (DC) are the most promising [210, 211]. In a phase I clinical trial with 12 GBM patients (7 newly diagnosed GBM and 5 recurrent GBM) the administration of autologous DC vaccines showed that this treatment was well tolerated and minimally toxic. Additionally, it revealed promising outcome results, such as 2 long term-survivors (≥4 years) and OS of 23.4 months; however, the benefit in clinical outcomes were mainly observed in patients with stable disease and low levels of TGF-β2, who also had a higher number of infiltrating cytotoxic T-cells in the tumor bulk, suggesting that this treatment may favor particularly these patients [212]. In another phase I/II clinical trial with patients with recurrent GBM, it was found more beneficial the treatment with mature DC vs. non-mature DC, as well as intradermal and intratumoral administration of the DC pulsed with autologous tumor lysate, compared to intradermal approach alone [213]. The transfer of ex vivo maturated immune cells like effector T cells or lymphokine activated killer cells (LAK) is also under clinical evaluation for GBM immunotherapy [214].

4.4. Current challenges and future trends

As illustrated by the vast panoply of drugs and therapeutic strategies under investigation for the treatment of GBM, there is a major effort to develop more effective therapies to treat this highly malignant and therapy-insensitive disease. Unfortunately, the success of these new therapies has mostly been somewhat disappointing. Nevertheless, the efficacy of some of these approaches has yet to be determined. Of note, in addition to the strategies reviewed here, therapies targeting apoptotic elements (like Bcl-2, and inhibitor of apoptosis proteins), the mechanisms of resistance to TMZ (such as PARP and MGMT), or gene therapy to TP53, are also some examples of the search for an effective therapy for GBM [33]. Additionally, several developments were also made in helping surgeons with fluorescence-guided resection of the tumor and in radiotherapy [116]. In conclusion, the relevance of the effort to find a cure for GBM is unquestionable. However, despite the hard working search for a therapeutic strategy to reverse the poor outcomes of these patients, the standard treatment with TMZ and RT remains presently the best option. Future therapeutic trends for the treatment of GBM will have to: (i) include the new molecular classification of GBM; (ii) incorporate more efficient drug delivery systems to overcome blood-brain barrier restraints; and (iii) redirect the therapeutic choices to each patient, considering the specific molecular alterations of each tumor.


1 - H Ohgaki, P Kleihues, Genetic pathways to primary and secondary glioblastoma. The American journal of pathology. 2007May;170 5 1445 53
2 - K. R Porter, B. J Mccarthy, S Freels, Y Kim, F. G Davis, Prevalence estimates for primary brain tumors in the United States by age, gender, behavior, and histology. Neuro Oncol. 2010Jun;12 6 520 7
3 - CBTRUSPrimary Brain and Other Nervous System Tumors, Estimated Number of Cases Overall and by Behavior by State, 2012Primary Malignant Brain and Other Nervous System Tumors, Estimated Number of Deaths by State, 2012. http://wwwcbtrusorg/2007 2008html2012.
4 - N. G Burnet, S. J Jefferies, R. J Benson, D. P Hunt, F. P Treasure, Years of life lost (YLL) from cancer is an important measure of population burden--and should be considered when allocating research funds. British journal of cancer. 2005Jan 31;92 2 241 5
5 - R Stupp, W. P Mason, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005Mar 10;352 10 987 96
6 - D. N Louis, H Ohgaki, O. D Wiestler, W. K Cavenee, P. C Burger, A Jouvet, et alThe 2007 WHO classification of tumours of the central nervous system. Acta neuropathologica. 2007Aug;114 2 97 109
7 - L. V Nguyen, R Vanner, P Dirks, C. J Eaves, Cancer stem cells: an evolving concept. Nat Rev Cancer. 2012Feb;12 2 133 43
8 - P. B Dirks, Brain tumor stem cells: bringing order to the chaos of brain cancer. J Clin Oncol. 2008Jun 10;26 17 2916 24
9 - N. A Charles, E. C Holland, R Gilbertson, R Glass, H Kettenmann, The brain tumor microenvironment. Glia. 2012Mar;60 3 502 14
10 - R. M Heywood, H. J Marcus, D. J Ryan, S. G Piccirillo, T. M Al-mayhani, C Watts, A review of the role of stem cells in the development and treatment of glioma. Acta Neurochir (Wien). 2012Jun;154 6 951 69discussion 69.
11 - R. M Bachoo, E. A Maher, K. L Ligon, N. E Sharpless, S. S Chan, M. J You, et alEpidermal growth factor receptor and Ink4a/Arf: convergent mechanisms governing terminal differentiation and transformation along the neural stem cell to astrocyte axis. Cancer cell. 2002Apr;1 3 269 77
12 - F Doetsch, I Caille, D. A Lim, J. M Garcia-verdugo, A Alvarez-buylla, Subventricular zone astrocytes are neural stem cells in the adult mammalian brain. Cell. 1999Jun 11;97 6 703 16
13 - E. D Laywell, P Rakic, V. G Kukekov, E. C Holland, D. A Steindler, Identification of a multipotent astrocytic stem cell in the immature and adult mouse brain. Proc Natl Acad Sci U S A. 2000Dec 5;97 25 13883 8
14 - J Chen, R. M Mckay, L. F Parada, Malignant glioma: lessons from genomics, mouse models, and stem cells. Cell. 2012Mar 30;149 1 36 47
15 - A. L Vescovi, R Galli, B. A Reynolds, Brain tumour stem cells. Nat Rev Cancer. 2006Jun;6 6 425 36
16 - R Chen, M. C Nishimura, S. M Bumbaca, S Kharbanda, W. F Forrest, I. M Kasman, et alA hierarchy of self-renewing tumor-initiating cell types in glioblastoma. Cancer cell. 2010Apr 13;17 4 362 75
17 - C. D Stiles, D. H Rowitch, Glioma stem cells: a midterm exam. Neuron. 2008Jun 26;58 6 832 46
18 - S. K Singh, C Hawkins, I. D Clarke, J. A Squire, J Bayani, T Hide, et alIdentification of human brain tumour initiating cells. Nature. 2004Nov 18;432 7015 396 401
19 - P. B Dirks, Brain tumor stem cells: the cancer stem cell hypothesis writ large. Molecular oncology. 2010Oct;4 5 420 30
20 - P Brescia, C Richichi, G Pelicci, Current strategies for identification of glioma stem cells: adequate or unsatisfactory? Journal of oncology. 2012
21 - M Jhanwar-uniyal, L Albert, E Mckenna, M Karsy, P Rajdev, A Braun, et alDeciphering the signaling pathways of cancer stem cells of glioblastoma multiforme: role of Akt/mTOR and MAPK pathways. Advances in enzyme regulation. 2011 51 1 164 70
22 - G. P Dunn, M. L Rinne, J Wykosky, G Genovese, S. N Quayle, I. F Dunn, et alEmerging insights into the molecular and cellular basis of glioblastoma. Genes Dev. 2012Apr 15;26 8 756 84
23 - L Cheng, S Bao, J. N Rich, Potential therapeutic implications of cancer stem cells in glioblastoma. Biochem Pharmacol. 2010Sep 1;80 5 654 65
24 - F Ohka, A Natsume, T Wakabayashi, Current trends in targeted therapies for glioblastoma multiforme. Neurol Res Int. 2012
25 - S. K Lim, S. R Llaguno, R. M Mckay, L. F Parada, Glioblastoma multiforme: a perspective on recent findings in human cancer and mouse models. BMB Rep. 2011Mar;44 3 158 64
26 - TCGAComprehensive genomic characterization defines human glioblastoma genes and core pathway. Nature. 2008 23 October 2008 455 7216 1061 8
27 - C. J Sherr, F Mccormick, R. B The, and 53pathways in cancer. Cancer Cell. 2002Aug;2(2):103-12.
28 - G. I Shapiro, Cyclin-dependent kinase pathways as targets for cancer treatment. J Clin Oncol. 2006Apr 10;24 11 1770 83
29 - H Mao, D. G Lebrun, J Yang, V. F Zhu, M Li, Deregulated signaling pathways in glioblastoma multiforme: molecular mechanisms and therapeutic targets. Cancer Invest. 2012Jan;30 1 48 56
30 - S. P Deb, Cell cycle regulatory functions of the human oncoprotein MDM2. Mol Cancer Res. 2003Dec;1 14 1009 16
31 - T Iwakuma, G Lozano, MDM2, an introduction. Mol Cancer Res. 2003Dec;1 14 993 1000
32 - Y Zhang, Y Xiong, W. G Yarbrough, ARF promotes MDM2 degradation and stabilizes 53ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell. 1998Mar 20;92(6):725-34.
33 - C Krakstad, M Chekenya, Survival signalling and apoptosis resistance in glioblastomas: opportunities for targeted therapeutics. Mol Cancer. 2010
34 - D. K Moscatello, M Holgado-madruga, D. R Emlet, R. B Montgomery, A. J Wong, Constitutive activation of phosphatidylinositol 3-kinase by a naturally occurring mutant epidermal growth factor receptor. J Biol Chem. 1998Jan 2;273 1 200 6
35 - B. M Costa, J. S Smith, Y Chen, J Chen, H. S Phillips, K. D Aldape, et alReversing HOXA9 oncogene activation by PI3K inhibition: epigenetic mechanism and prognostic significance in human glioblastoma. Cancer Res. 2010Jan 15;70 2 453 62
36 - N Gaspar, L Marshall, L Perryman, D. A Bax, S. E Little, M Viana-pereira, et alMGMT-independent temozolomide resistance in pediatric glioblastoma cells associated with a PI3-kinase-mediated HOX/stem cell gene signature. Cancer Res. 2010Nov 15;70 22 9243 52
37 - A Murat, E Migliavacca, T Gorlia, W. L Lambiv, T Shay, M. F Hamou, et alStem cell-related "self-renewal" signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma. J Clin Oncol. 2008Jun 20;26 18 3015 24
38 - L Dang, D. W White, S Gross, B. D Bennett, M. A Bittinger, E. M Driggers, et alCancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature. 2009Dec 10;462 7274 739 44
39 - M Sasaki, C. B Knobbe, J. C Munger, E. F Lind, D Brenner, A Brustle, et alIDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics. Nature. 2012Jul 4.
40 - R. G Verhaak, K. A Hoadley, E Purdom, V Wang, Y Qi, M. D Wilkerson, et alIntegrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010Jan 19;17 1 98 110
41 - Y Liang, M Diehn, N Watson, A. W Bollen, K. D Aldape, M. K Nicholas, et alGene expression profiling reveals molecularly and clinically distinct subtypes of glioblastoma multiforme. Proc Natl Acad Sci U S A. 2005Apr 19;102 16 5814 9
42 - P. S Mischel, R Shai, T Shi, S Horvath, K. V Lu, G Choe, et alIdentification of molecular subtypes of glioblastoma by gene expression profiling. Oncogene. 2003Apr 17;22 15 2361 73
43 - R Shai, T Shi, T. J Kremen, S Horvath, L. M Liau, T. F Cloughesy, et alGene expression profiling identifies molecular subtypes of gliomas. Oncogene. 2003Jul 31;22 31 4918 23
44 - W. A Freije, F. E Castro-vargas, Z Fang, S Horvath, T Cloughesy, L. M Liau, et alGene expression profiling of gliomas strongly predicts survival. Cancer Res. 2004Sep 15;64 18 6503 10
45 - C. L Nutt, D. R Mani, R. A Betensky, P Tamayo, J. G Cairncross, C Ladd, et alGene expression-based classification of malignant gliomas correlates better with survival than histological classification. Cancer Res. 2003Apr 1;63 7 1602 7
46 - H. S Phillips, S Kharbanda, R Chen, W. F Forrest, R. H Soriano, T. D Wu, et alMolecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell. 2006Mar;9 3 157 73
47 - C. L Tso, W. A Freije, A Day, Z Chen, B Merriman, A Perlina, et alDistinct transcription profiles of primary and secondary glioblastoma subgroups. Cancer Res. 2006Jan 1;66 1 159 67
48 - W. J Curran, Jr., Scott CB, Horton J, Nelson JS, Weinstein AS, Fischbach AJ, et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst. 1993May 5;85 9 704 10
49 - S Bao, Q Wu, R. E Mclendon, Y Hao, Q Shi, A. B Hjelmeland, et alGlioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 2006Dec 7;444 7120 756 60
50 - A Chakravarti, G Zhai, Y Suzuki, S Sarkesh, P. M Black, A Muzikansky, et alThe prognostic significance of phosphatidylinositol 3-kinase pathway activation in human gliomas. J Clin Oncol. 2004May 15;22 10 1926 33
51 - D. A Haas-kogan, M. D Prados, K. R Lamborn, T Tihan, M. S Berger, D Stokoe, Biomarkers to predict response to epidermal growth factor receptor inhibitors. Cell Cycle. 2005Oct;4 10 1369 72
52 - M. E Hegi, A. C Diserens, T Gorlia, M. F Hamou, N De Tribolet, M Weller, et alMGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005Mar 10;352 10 997 1003
53 - A Hormigo, B Gu, S Karimi, E Riedel, K. S Panageas, M. A Edgar, et alYKL-40 and matrix metalloproteinase-9 as potential serum biomarkers for patients with high-grade gliomas. Clin Cancer Res. 2006Oct 1;12 19 5698 704
54 - G Liu, X Yuan, Z Zeng, P Tunici, H Ng, I. R Abdulkadir, et alAnalysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol Cancer. 2006
55 - I. K Mellinghoff, M. Y Wang, I Vivanco, D. A Haas-kogan, S Zhu, E. Q Dia, et alMolecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med. 2005Nov 10;353 19 2012 24
56 - J. M Nigro, A Misra, L Zhang, I Smirnov, H Colman, C Griffin, et alIntegrated array-comparative genomic hybridization and expression array profiles identify clinically relevant molecular subtypes of glioblastoma. Cancer Res. 2005Mar 1;65 5 1678 86
57 - D. W Parsons, S Jones, X Zhang, J. C Lin, R. J Leary, P Angenendt, et alAn integrated genomic analysis of human glioblastoma multiforme. Science. 2008Sep 26;321 5897 1807 12
58 - C. E Pelloski, E Lin, L Zhang, W. K Yung, H Colman, J. L Liu, et alPrognostic associations of activated mitogen-activated protein kinase and Akt pathways in glioblastoma. Clin Cancer Res. 2006Jul 1;12 13 3935 41
59 - S Srinivasan, I. R Patric, K Somasundaram, A ten-microRNA expression signature predicts survival in glioblastoma. PLoS One. 2011e17438.
60 - H Colman, K Aldape, Molecular predictors in glioblastoma: toward personalized therapy. Arch Neurol. 2008Jul;65 7 877 83
61 - L Liu, S Markowitz, S. L Gerson, Mismatch repair mutations override alkyltransferase in conferring resistance to temozolomide but not to 1,3-bis(2-chloroethyl)nitrosourea. Cancer Res. 1996Dec 1;56 23 5375 9
62 - B. M Costa, C Caeiro, I Guimaraes, O Martinho, T Jaraquemada, I Augusto, et alPrognostic value of MGMT promoter methylation in glioblastoma patients treated with temozolomide-based chemoradiation: a Portuguese multicentre study. Oncol Rep. 2010Jun;23 6 1655 62
63 - I. J Van Vlodrop, H. E Niessen, S Derks, M. M Baldewijns, W Van Criekinge, J. G Herman, et alAnalysis of promoter CpG island hypermethylation in cancer: location, location, location! Clin Cancer Res. 2011Jul 1;17 13 4225 31
64 - P Bady, D Sciuscio, A. C Diserens, J Bloch, van den Bent MJ, Marosi C, et al. MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status. Acta Neuropathol. 2012Jul 19.
65 - N Shah, B Lin, Z Sibenaller, T Ryken, H Lee, J. G Yoon, et alComprehensive analysis of MGMT promoter methylation: correlation with MGMT expression and clinical response in GBM. PLoS One. 2011e16146.
66 - W Wick, M Platten, C Meisner, J Felsberg, G Tabatabai, M Simon, et alTemozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol. 2012Jul;13 7 707 15
67 - R. A Olson, P. K Brastianos, D. A Palma, Prognostic and predictive value of epigenetic silencing of MGMT in patients with high grade gliomas: a systematic review and meta-analysis. J Neurooncol. 2011Nov;105 2 325 35
68 - H Yan, D. W Parsons, G Jin, R Mclendon, B. A Rasheed, W Yuan, et alIDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009Feb 19;360 8 765 73
69 - D. E Koshland, Jr., Walsh K, LaPorte DC. Sensitivity of metabolic fluxes to covalent control. Curr Top Cell Regul. 1985 27 13 22
70 - S Zhao, Y Lin, W Xu, W Jiang, Z Zha, P Wang, et alGlioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha. Science. 2009Apr 10;324 5924 261 5
71 - J Balss, J Meyer, W Mueller, A Korshunov, C Hartmann, A Von Deimling, Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol. 2008Dec;116 6 597 602
72 - K Ichimura, D. M Pearson, S Kocialkowski, L. M Backlund, R Chan, D. T Jones, et alIDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. Neuro Oncol. 2009Aug;11 4 341 7
73 - C Hartmann, J Meyer, J Balss, D Capper, W Mueller, A Christians, et alType and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathol. 2009Oct;118 4 469 74
74 - M Sanson, Y Marie, S Paris, A Idbaih, J Laffaire, F Ducray, et alIsocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol. 2009Sep 1;27 25 4150 4
75 - H Noushmehr, D. J Weisenberger, K Diefes, H. S Phillips, K Pujara, B. P Berman, et alIdentification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell. 2010May 18;17 5 510 22
76 - K. E Yen, M. A Bittinger, S. M Su, V. R Fantin, Cancer-associated IDH mutations: biomarker and therapeutic opportunities. Oncogene. 2010Dec 9;29 49 6409 17
77 - SongTao QLei Y, Si G, YanQing D, HuiXia H, XueLin Z, et al. IDH mutations predict longer survival and response to temozolomide in secondary glioblastoma. Cancer Sci. 2012Feb;103 2 269 73
78 - W Mcginnis, R Krumlauf, Homeobox genes and axial patterning. Cell. 1992Jan 24;68 2 283 302
79 - D. M Wellik, Hox genes and vertebrate axial pattern. Curr Top Dev Biol. 2009 88 257 78
80 - N Shah, S Sukumar, The Hox genes and their roles in oncogenesis. Nat Rev Cancer. 2010May;10 5 361 71
81 - C Abate-shen, Deregulated homeobox gene expression in cancer: cause or consequence? Nat Rev Cancer. 2002Oct;2 10 777 85
82 - A Care, F Felicetti, E Meccia, L Bottero, M Parenza, A Stoppacciaro, et alHOXB7: a key factor for tumor-associated angiogenic switch. Cancer Res. 2001Sep 1;61 17 6532 9
83 - Y. L Hu, S Fong, C Ferrell, C Largman, W. F Shen, HOXA9 modulates its oncogenic partner Meis1 to influence normal hematopoiesis. Mol Cell Biol. 2009Sep;29 18 5181 92
84 - V Raman, S. A Martensen, D Reisman, E Evron, W. F Odenwald, E Jaffee, et alCompromised HOXA5 function can limit 53expression in human breast tumours. Nature. 2000Jun 22;405(6789):974-8.
85 - X Wu, H Chen, B Parker, E Rubin, T Zhu, J. S Lee, et alHOXB7, a homeodomain protein, is overexpressed in breast cancer and confers epithelial-mesenchymal transition. Cancer Res. 2006Oct 1;66 19 9527 34
86 - R Abdel-fattah, A Xiao, D Bomgardner, C. S Pease, M. B Lopes, I. M Hussaini, Differential expression of HOX genes in neoplastic and non-neoplastic human astrocytes. J Pathol. 2006May;209 1 15 24
87 - D Brandsma, L Stalpers, W Taal, P Sminia, van den Bent MJ. Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol. 2008May;9 5 453 61
88 - P. Y Wen, S Kesari, Malignant gliomas in adults. N Engl J Med. 2008Jul 31;359 5 492 507
89 - A. G Sorensen, T. T Batchelor, P. Y Wen, W. T Zhang, R. K Jain, Response criteria for glioma. Nat Clin Pract Oncol. 2008Nov;5 11 634 44
90 - van den Bent MJVogelbaum MA, Wen PY, Macdonald DR, Chang SM. End point assessment in gliomas: novel treatments limit usefulness of classical Macdonald’s Criteria. J Clin Oncol. 2009Jun 20;27 18 2905 8
91 - M. K Tanwar, M. R Gilbert, E. C Holland, Gene expression microarray analysis reveals YKL-40 to be a potential serum marker for malignant character in human glioma. Cancer Res. 2002Aug 1;62 15 4364 8
92 - K. P Bhat, C. E Pelloski, Y Zhang, S. H Kim, deLaCruz C, Rehli M, et al. Selective repression of YKL-40 by NF-kappaB in glioma cell lines involves recruitment of histone deacetylase-1 and-2. FEBS Lett. 2008Sep 22;582(21-22):3193-200.
93 - J. S Johansen, N. A Schultz, B. V Jensen, Plasma YKL-40: a potential new cancer biomarker? Future Oncol. 2009Sep;5 7 1065 82
94 - R Shao, K Hamel, L Petersen, Q. J Cao, R. B Arenas, C Bigelow, et alYKL-40, a secreted glycoprotein, promotes tumor angiogenesis. Oncogene. 2009Dec 17;28 50 4456 68
95 - D Bernardi, A Padoan, A Ballin, M Sartori, R Manara, R Scienza, et alSerum YKL-40 following resection for cerebral glioblastoma. J Neurooncol. 2012Apr;107 2 299 305
96 - F. M Iwamoto, A. F Hottinger, S Karimi, E Riedel, J Dantis, M Jahdi, et alSerum YKL-40 is a marker of prognosis and disease status in high-grade gliomas. Neuro Oncol. 2011Nov;13 11 1244 51
97 - C. E Pelloski, A Mahajan, M Maor, E. L Chang, S Woo, M Gilbert, et alYKL-40 expression is associated with poorer response to radiation and shorter overall survival in glioblastoma. Clin Cancer Res. 2005May 1;11 9 3326 34
98 - R. Y Bai, V Staedtke, G. J Riggins, Molecular targeting of glioblastoma: Drug discovery and therapies. Trends Mol Med. 2011Jun;17 6 301 12
99 - T. S Jones, E. C Holland, Standard of care therapy for malignant glioma and its effect on tumor and stromal cells. Oncogene. 2012Apr 19;31 16 1995 2006
100 - J. L Villano, T. E Seery, L. R Bressler, Temozolomide in malignant gliomas: current use and future targets. Cancer Chemother Pharmacol. 2009Sep;64 4 647 55
101 - M. H Cohen, Y. L Shen, P Keegan, R Pazdur, FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme. The oncologist. 2009Nov;14 11 1131 8
102 - E Pan, S. B Mitchell, J. S Tsai, A retrospective study of the safety of BCNU wafers with concurrent temozolomide and radiotherapy and adjuvant temozolomide for newly diagnosed glioblastoma patients. J Neurooncol. 2008Jul;88 3 353 7
103 - M Preusser, S De Ribaupierre, A Wohrer, S. C Erridge, M Hegi, M Weller, et alCurrent concepts and management of glioblastoma. Ann Neurol. 2011Jul;70 1 9 21
104 - M. M Mrugala, M. C Chamberlain, Mechanisms of disease: temozolomide and glioblastoma--look to the future. Nature clinical practice Oncology. 2008Aug;5 8 476 86
105 - R Stupp, M. E Hegi, W. P Mason, van den Bent MJ, Taphoorn MJ, Janzer RC, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009May;10 5 459 66
106 - J Clarke, N Butowski, S Chang, Recent advances in therapy for glioblastoma. Archives of neurology. 2010Mar;67 3 279 83
107 - (FDA) USFaDABevacizumab Injection. [updated 03/08/2012Available from:
108 - B Hasselbalch, U Lassen, S Hansen, M Holmberg, M Sorensen, M Kosteljanetz, et alCetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: a phase II trial. Neuro Oncol. 2010May;12 5 508 16
109 - A Lai, A Tran, P. L Nghiemphu, W. B Pope, O. E Solis, M Selch, et alPhase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. J Clin Oncol. 2011Jan 10;29 2 142 8
110 - T. N Kreisl, L Kim, K Moore, P Duic, C Royce, I Stroud, et alPhase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol. 2009Feb 10;27 5 740 5
111 - J. F De Groot, G Fuller, A. J Kumar, Y Piao, K Eterovic, Y Ji, et alTumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice. Neuro Oncol. 2010Mar;12 3 233 42
112 - O Keunen, M Johansson, A Oudin, M Sanzey, S. A Rahim, F Fack, et alAnti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma. Proc Natl Acad Sci U S A. 2011Mar 1;108 9 3749 54
113 - W Wick, M Weller, M Weiler, T Batchelor, A. W Yung, M Platten, Pathway inhibition: emerging molecular targets for treating glioblastoma. Neuro Oncol. 2011Jun;13 6 566 79
114 - O. O Kanu, B Hughes, C Di, N Lin, J Fu, D. D Bigner, et alGlioblastoma Multiforme Oncogenomics and Signaling Pathways. Clin Med Oncol. 2009Apr 8;3 39 52
115 - M. A Lemmon, J Schlessinger, Cell signaling by receptor tyrosine kinases. Cell. 2010Jun 25;141 7 1117 34
116 - E. G Van Meir, C. G Hadjipanayis, A. D Norden, H. K Shu, P. Y Wen, J. J Olson, Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma. CA Cancer J Clin. 2010May-Jun;60 3 166 93
117 - M. H Cohen, J. R Johnson, Y. F Chen, R Sridhara, R Pazdur, FDA drug approval summary: erlotinib (Tarceva) tablets. The oncologist. 2005Aug;10 7 461 6
118 - ClinicalTrialsgov- a service of the U.S. National Institutes of Health. [27 July 2012Available from:
119 - J Polivka, Jr., Polivka J, Rohan V, Topolcan O, Ferda J. New molecularly targeted therapies for glioblastoma multiforme. Anticancer Res. 2012Jul;32 7 2935 46
120 - J Fukai, K Nishio, T Itakura, F Koizumi, Antitumor activity of cetuximab against malignant glioma cells overexpressing EGFR deletion mutant variant III. Cancer Sci. 2008Oct;99 10 2062 9
121 - T Martens, Y Laabs, H. S Gunther, D Kemming, Z Zhu, L Witte, et alInhibition of glioblastoma growth in a highly invasive nude mouse model can be achieved by targeting epidermal growth factor receptor but not vascular endothelial growth factor receptor-2. Clin Cancer Res. 2008Sep 1;14 17 5447 58
122 - B Neyns, J Sadones, E Joosens, F Bouttens, L Verbeke, J. F Baurain, et alStratified phase II trial of cetuximab in patients with recurrent high-grade glioma. Ann Oncol. 2009Sep;20 9 1596 603
123 - H. K Gan, A. H Kaye, R. B Luwor, The EGFRvIII variant in glioblastoma multiforme. J Clin Neurosci. 2009Jun;16 6 748 54
124 - A. B Heimberger, J. H Sampson, The PEPvIII-KLH (CDX-110) vaccine in glioblastoma multiforme patients. Expert Opin Biol Ther. 2009Aug;9 8 1087 98
125 - J. H Sampson, A. B Heimberger, G. E Archer, K. D Aldape, A. H Friedman, H. S Friedman, et alImmunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J Clin Oncol. 2010Nov 1;28 31 4722 9
126 - D. A Reardon, M. J Egorin, J. A Quinn, J. N Rich, S Gururangan, J. J Vredenburgh, et alPhase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme. J Clin Oncol. 2005Dec 20;23 36 9359 68
127 - E Ranza, G Mazzini, A Facoetti, R Nano, In-vitro effects of the tyrosine kinase inhibitor imatinib on glioblastoma cell proliferation. J Neurooncol. 2010Feb;96 3 349 57
128 - T Kilic, J. A Alberta, P. R Zdunek, M Acar, P Iannarelli, O Reilly, T, et al. Intracranial inhibition of platelet-derived growth factor-mediated glioblastoma cell growth by an orally active kinase inhibitor of the 2-phenylaminopyrimidine class. Cancer Res. 2000Sep 15;60 18 5143 50
129 - D. A Reardon, G Dresemann, S Taillibert, M Campone, van den Bent M, Clement P, et al. Multicentre phase II studies evaluating imatinib plus hydroxyurea in patients with progressive glioblastoma. Br J Cancer. 2009Dec 15;101 12 1995 2004
130 - E Raymond, A. A Brandes, C Dittrich, P Fumoleau, B Coudert, P. M Clement, et alPhase II study of imatinib in patients with recurrent gliomas of various histologies: a European Organisation for Research and Treatment of Cancer Brain Tumor Group Study. J Clin Oncol. 2008Oct 1;26 28 4659 65
131 - P. Y Wen, W. K Yung, K. R Lamborn, P. L Dahia, Y Wang, B Peng, et alPhase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08. Clin Cancer Res. 2006Aug 15;12 16 4899 907
132 - D. A Reardon, M. J Egorin, A Desjardins, J. J Vredenburgh, J. H Beumer, T. F Lagattuta, et alPhase I pharmacokinetic study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea for malignant glioma. Cancer. 2009May 15;115 10 2188 98
133 - S Agarwal, R Sane, R Oberoi, J. R Ohlfest, W. F Elmquist, Delivery of molecularly targeted therapy to malignant glioma, a disease of the whole brain. Expert Rev Mol Med. 2011e17.
134 - E. R Gerstner, P. J Chen, P. Y Wen, R. K Jain, T. T Batchelor, G Sorensen, Infiltrative patterns of glioblastoma spread detected via diffusion MRI after treatment with cediranib. Neuro Oncol. 2010May;12 5 466 72
135 - W. S Kamoun, C. D Ley, C. T Farrar, A. M Duyverman, J Lahdenranta, D. A Lacorre, et alEdema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice. J Clin Oncol. 2009May 20;27 15 2542 52
136 - J. P Eder, Vande Woude GF, Boerner SA, LoRusso PM. Novel therapeutic inhibitors of the c-Met signaling pathway in cancer. Clin Cancer Res. 2009Apr 1;15 7 2207 14
137 - D. S Kong, S. Y Song, D. H Kim, K. M Joo, J. S Yoo, J. S Koh, et alPrognostic significance of c-Met expression in glioblastomas. Cancer. 2009Jan 1;115 1 140 8
138 - J. S De Bono, Yap TA. c-MET: an exciting new target for anticancer therapy. Ther Adv Med Oncol. 2011Nov;3(1 Suppl):S3 5
139 - G Tabatabai, M Weller, B Nabors, M Picard, D Reardon, T Mikkelsen, et alTargeting integrins in malignant glioma. Target Oncol. 2010Sep;5 3 175 81
140 - S Loges, M Butzal, J Otten, M Schweizer, U Fischer, C Bokemeyer, et alCilengitide inhibits proliferation and differentiation of human endothelial progenitor cells in vitro. Biochem Biophys Res Commun. 2007Jun 15;357 4 1016 20
141 - G. D Maurer, I Tritschler, B Adams, G Tabatabai, W Wick, R Stupp, et alCilengitide modulates attachment and viability of human glioma cells, but not sensitivity to irradiation or temozolomide in vitro. Neuro Oncol. 2009Dec;11 6 747 56
142 - T. N Kreisl, L Kim, K Moore, P Duic, S Kotliarova, J Walling, et alA phase I trial of enzastaurin in patients with recurrent gliomas. Clin Cancer Res. 2009May 15;15 10 3617 23
143 - J. R Graff, A. M Mcnulty, K. R Hanna, B. W Konicek, R. L Lynch, S. N Bailey, et alThe protein kinase Cbeta-selective inhibitor, Enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts. Cancer Res. 2005Aug 15;65 16 7462 9
144 - W Wick, V. K Puduvalli, M. C Chamberlain, van den Bent MJ, Carpentier AF, Cher LM, et al. Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. J Clin Oncol. 2010Mar 1;28 7 1168 74
145 - K. L Pitter, C. J Galban, S Galban, O. S Tehrani, F Li, N Charles, et alPerifosine and CCI 779 co-operate to induce cell death and decrease proliferation in PTEN-intact and PTEN-deficient PDGF-driven murine glioblastoma. PLoS One. 2011e14545.
146 - J. J Gills, J Lopiccolo, P. A Dennis, Nelfinavir, a new anti-cancer drug with pleiotropic effects and many paths to autophagy. Autophagy. 2008Jan;4 1 107 9
147 - P Pyrko, A Kardosh, W Wang, W Xiong, A. H Schonthal, T. C Chen, HIV-1 protease inhibitors nelfinavir and atazanavir induce malignant glioma death by triggering endoplasmic reticulum stress. Cancer Res. 2007Nov 15;67 22 10920 8
148 - Z Jiang, N Pore, G. J Cerniglia, R Mick, M. M Georgescu, E. J Bernhard, et alPhosphatase and tensin homologue deficiency in glioblastoma confers resistance to radiation and temozolomide that is reversed by the protease inhibitor nelfinavir. Cancer Res. 2007May 1;67 9 4467 73
149 - N Pore, A. K Gupta, G. J Cerniglia, A Maity, HIV protease inhibitors decrease VEGF/HIF-1alpha expression and angiogenesis in glioblastoma cells. Neoplasia. 2006Nov;8 11 889 95
150 - T. A Yap, M. D Garrett, M. I Walton, F Raynaud, J. S De Bono, P Workman, Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises. Curr Opin Pharmacol. 2008Aug;8 4 393 412
151 - L Han, Y Yang, X Yue, K Huang, X Liu, P Pu, et alInactivation of PI3K/AKT signaling inhibits glioma cell growth through modulation of beta-catenin-mediated transcription. Brain Res. 2010Dec 17;1366 9 17
152 - L Chen, L Han, Z Shi, K Zhang, Y Liu, Y Zheng, et alLY294002 enhances cytotoxicity of temozolomide in glioma by down-regulation of the PI3K/Akt pathway. Mol Med Report. 2012Feb;5 2 575 9
153 - J Sunayama, A Sato, K Matsuda, K Tachibana, K Suzuki, Y Narita, et alDual blocking of mTor and PI3K elicits a prodifferentiation effect on glioblastoma stem-like cells. Neuro Oncol. 2010Dec;12 12 1205 19
154 - L. H Wei, H Su, I. J Hildebrandt, M. E Phelps, J Czernin, W. A Weber, Changes in tumor metabolism as readout for Mammalian target of rapamycin kinase inhibition by rapamycin in glioblastoma. Clin Cancer Res. 2008Jun 1;14 11 3416 26
155 - R. K Goudar, Q Shi, M. D Hjelmeland, S. T Keir, R. E Mclendon, C. J Wikstrand, et alCombination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition. Mol Cancer Ther. 2005Jan;4 1 101 12
156 - P Liu, H Cheng, T. M Roberts, J. J Zhao, Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov. 2009Aug;8 8 627 44
157 - C. M Chresta, B. R Davies, I Hickson, T Harding, S Cosulich, S. E Critchlow, et alAZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity. Cancer Res. 2010Jan 1;70 1 288 98
158 - F Yang, C Brown, R Buettner, M Hedvat, R Starr, A Scuto, et alSorafenib induces growth arrest and apoptosis of human glioblastoma cells through the dephosphorylation of signal transducers and activators of transcription 3. Mol Cancer Ther. 2010Apr;9 4 953 62
159 - J. E Bolden, M. J Peart, R. W Johnstone, Anticancer activities of histone deacetylase inhibitors. Nature reviews Drug discovery. 2006Sep;5 9 769 84
160 - W. S Xu, R. B Parmigiani, P. A Marks, Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene. 2007Aug 13;26 37 5541 52
161 - J. M Wagner, B Hackanson, M Lubbert, M Jung, Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy. Clin Epigenetics. 2010Dec;1(3-4):117-36.
162 - M Weller, T Gorlia, J. G Cairncross, van den Bent MJ, Mason W, Belanger K, et al. Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma. Neurology. 2011Sep 20;77 12 1156 64
163 - M Dokmanovic, C Clarke, P. A Marks, Histone deacetylase inhibitors: overview and perspectives. Mol Cancer Res. 2007Oct;5 10 981 9
164 - C. H Ryu, W. S Yoon, K. Y Park, S. M Kim, J. Y Lim, J. S Woo, et alValproic Acid Downregulates the Expression of MGMT and Sensitizes Temozolomide-Resistant Glioma Cells. J Biomed Biotechnol. 2012
165 - K. A Van Nifterik, Van den Berg J, Slotman BJ, Lafleur MV, Sminia P, Stalpers LJ. Valproic acid sensitizes human glioma cells for temozolomide and gamma-radiation. J Neurooncol. 2012Mar;107 1 61 7
166 - C. H Chen, Y. J Chang, M. S Ku, K. T Chung, J. T Yang, Enhancement of temozolomide-induced apoptosis by valproic acid in human glioma cell lines through redox regulation. J Mol Med (Berl). 2011Mar;89 3 303 15
167 - S Krishnan, P. D Brown, K. V Ballman, J. B Fiveash, J. H Uhm, C Giannini, et alPhase I trial of erlotinib with radiation therapy in patients with glioblastoma multiforme: results of North Central Cancer Treatment Group protocol N0177. Int J Radiat Oncol Biol Phys. 2006Jul 15;65 4 1192 9
168 - J. F De Groot, M. R Gilbert, K Aldape, K. R Hess, T. A Hanna, S Ictech, et alPhase II study of carboplatin and erlotinib (Tarceva, OSI-774) in patients with recurrent glioblastoma. J Neurooncol. 2008Oct;90 1 89 97
169 - M. D Prados, S. M Chang, N Butowski, R Deboer, R Parvataneni, H Carliner, et alPhase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma. J Clin Oncol. 2009Feb 1;27 4 579 84
170 - J. J Raizer, L. E Abrey, A. B Lassman, S. M Chang, K. R Lamborn, J. G Kuhn, et alA phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy. Neuro Oncol. 2010Jan;12 1 95 103
171 - J. J Raizer, L. E Abrey, A. B Lassman, S. M Chang, K. R Lamborn, J. G Kuhn, et alA phase I trial of erlotinib in patients with nonprogressive glioblastoma multiforme postradiation therapy, and recurrent malignant gliomas and meningiomas. Neuro Oncol. 2010Jan;12 1 87 94
172 - D. A Reardon, A Desjardins, J. J Vredenburgh, S Gururangan, A. H Friedman, J. E Herndon, nd, et alPhase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma. J Neurooncol. 2010Jan;96 2 219 30
173 - S Sathornsumetee, A Desjardins, J. J Vredenburgh, R. E Mclendon, J Marcello, J. E Herndon, et alPhase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma. Neuro Oncol. 2010Dec;12 12 1300 10
174 - van den Bent MJBrandes AA, Rampling R, Kouwenhoven MC, Kros JM, Carpentier AF, et al. Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034. J Clin Oncol. 2009Mar 10;27 8 1268 74
175 - P. D Brown, S Krishnan, J. N Sarkaria, W Wu, K. A Jaeckle, J. H Uhm, et alPhase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177. J Clin Oncol. 2008Dec 1;26 34 5603 9
176 - M. E Hegi, A. C Diserens, P Bady, Y Kamoshima, M. C Kouwenhoven, M Delorenzi, et alPathway analysis of glioblastoma tissue after preoperative treatment with the EGFR tyrosine kinase inhibitor gefitinib--a phase II trial. Mol Cancer Ther. 2011Jun;10 6 1102 12
177 - J. N Rich, D. A Reardon, T Peery, J. M Dowell, J. A Quinn, K. L Penne, et alPhase II trial of gefitinib in recurrent glioblastoma. J Clin Oncol. 2004Jan 1;22 1 133 42
178 - J. H Uhm, K. V Ballman, W Wu, C Giannini, J. C Krauss, J. C Buckner, et alPhase II evaluation of gefitinib in patients with newly diagnosed Grade 4 astrocytoma: Mayo/North Central Cancer Treatment Group Study N0074. Int J Radiat Oncol Biol Phys. 2011Jun 1;80 2 347 53
179 - E Razis, P Selviaridis, S Labropoulos, J. L Norris, M. J Zhu, D. D Song, et alPhase II study of neoadjuvant imatinib in glioblastoma: evaluation of clinical and molecular effects of the treatment. Clin Cancer Res. 2009Oct 1;15 19 6258 66
180 - G Dresemann, M Weller, M. A Rosenthal, U Wedding, W Wagner, E Engel, et alImatinib in combination with hydroxyurea versus hydroxyurea alone as oral therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide. J Neurooncol. 2010Feb;96 3 393 402
181 - T. T Batchelor, D. G Duda, di Tomaso E, Ancukiewicz M, Plotkin SR, Gerstner E, et al. Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J Clin Oncol. 2010Jun 10;28 17 2817 23
182 - A. G Sorensen, T. T Batchelor, W. T Zhang, P. J Chen, P Yeo, M Wang, et alA "vascular normalization index" as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients. Cancer Res. 2009Jul 1;69 13 5296 300
183 - P. Y Wen, D Schiff, T. F Cloughesy, J. J Raizer, J Laterra, M Smitt, et alA phase II study evaluating the efficacy and safety of AMG 102 (rilotumumab) in patients with recurrent glioblastoma. Neuro Oncol. 2011Apr;13 4 437 46
184 - N Butowski, S. M Chang, K. R Lamborn, M. Y Polley, R Pieper, J. F Costello, et alPhase II and pharmacogenomics study of enzastaurin plus temozolomide during and following radiation therapy in patients with newly diagnosed glioblastoma multiforme and gliosarcoma. Neuro Oncol. 2011Dec;13 12 1331 8
185 - T. N Kreisl, S Kotliarova, J. A Butman, P. S Albert, L Kim, L Musib, et alA phase I/II trial of enzastaurin in patients with recurrent high-grade gliomas. Neuro Oncol. 2010Feb;12 2 181 9
186 - J. D Hainsworth, K. C Shih, G. C Shepard, G. W Tillinghast, B. T Brinker, D. R Spigel, Phase II Study of Concurrent Radiation Therapy, Temozolomide, and Bevacizumab Followed by Bevacizumab/Everolimus as First-Line Treatment for Patients With Glioblastoma. Clin Adv Hematol Oncol. 2012Apr;10 4 240 6
187 - W. P Mason, M Macneil, P Kavan, J Easaw, D Macdonald, B Thiessen, et alA phase I study of temozolomide and everolimus (RAD001) in patients with newly diagnosed and progressive glioblastoma either receiving or not receiving enzyme-inducing anticonvulsants: an NCIC CTG study. Invest New Drugs. 2011Dec 9.
188 - J. N Sarkaria, E Galanis, W Wu, P. J Peller, C Giannini, P. D Brown, et alNorth Central Cancer Treatment Group Phase I trial N057K of everolimus (RAD001) and temozolomide in combination with radiation therapy in patients with newly diagnosed glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 2011Oct 1;81 2 468 75
189 - E Galanis, J. C Buckner, M. J Maurer, J. I Kreisberg, K Ballman, J Boni, et alPhase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. J Clin Oncol. 2005Aug 10;23 23 5294 304
190 - J. N Sarkaria, E Galanis, W Wu, A. B Dietz, T. J Kaufmann, M. P Gustafson, et alCombination of temsirolimus (CCI-779) with chemoradiation in newly diagnosed glioblastoma multiforme (GBM) (NCCTG trial N027D) is associated with increased infectious risks. Clin Cancer Res. 2010Nov 15;16 22 5573 80
191 - T. F Cloughesy, K Yoshimoto, P Nghiemphu, K Brown, J Dang, S Zhu, et alAntitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma. PLoS Med. 2008Jan 22;5(1):e8.
192 - R Lustig, T Mikkelsen, G Lesser, S Grossman, X Ye, S Desideri, et alPhase II preradiation R115777 (tipifarnib) in newly diagnosed GBM with residual enhancing disease. Neuro Oncol. 2008Dec;10 6 1004 9
193 - P. L Nghiemphu, P. Y Wen, K. R Lamborn, J Drappatz, H. I Robins, K Fink, et alA phase I trial of tipifarnib with radiation therapy, with and without temozolomide, for patients with newly diagnosed glioblastoma. Int J Radiat Oncol Biol Phys. 2011Dec 1;81 5 1422 7
194 - T. F Cloughesy, P. Y Wen, H. I Robins, S. M Chang, M. D Groves, K. L Fink, et alPhase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study. J Clin Oncol. 2006Aug 1;24 22 3651 6
195 - E. C Moyal, A Laprie, M Delannes, M Poublanc, I Catalaa, F Dalenc, et alPhase I trial of tipifarnib (R115777) concurrent with radiotherapy in patients with glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 2007Aug 1;68 5 1396 401
196 - J. D Hainsworth, T Ervin, E Friedman, V Priego, P. B Murphy, B. L Clark, et alConcurrent radiotherapy and temozolomide followed by temozolomide and sorafenib in the first-line treatment of patients with glioblastoma multiforme. Cancer. 2010Aug 1;116 15 3663 9
197 - D. A Reardon, J. J Vredenburgh, A Desjardins, K Peters, S Gururangan, J. H Sampson, et alEffect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma. J Neurooncol. 2011Jan;101 1 57 66
198 - L. B Nabors, T Mikkelsen, S. S Rosenfeld, F Hochberg, N. S Akella, J. D Fisher, et alPhase I and correlative biology study of cilengitide in patients with recurrent malignant glioma. J Clin Oncol. 2007May 1;25 13 1651 7
199 - D. A Reardon, K. L Fink, T Mikkelsen, T. F Cloughesy, O Neill, A Plotkin, S, et al. Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme. J Clin Oncol. 2008Dec 1;26 34 5610 7
200 - R Stupp, M. E Hegi, B Neyns, R Goldbrunner, U Schlegel, P. M Clement, et alPhase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. J Clin Oncol. 2010Jun 1;28 16 2712 8
201 - B. B Friday, S. K Anderson, J Buckner, C Yu, C Giannini, F Geoffroy, et alPhase II trial of vorinostat in combination with bortezomib in recurrent glioblastoma: a north central cancer treatment group study. Neuro Oncol. 2012Feb;14 2 215 21
202 - E Galanis, K. A Jaeckle, M. J Maurer, J. M Reid, M. M Ames, J. S Hardwick, et alPhase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study. J Clin Oncol. 2009Apr 20;27 12 2052 8
203 - F. M Iwamoto, K. R Lamborn, J. G Kuhn, P. Y Wen, W. K Yung, M. R Gilbert, et alA phase I/II trial of the histone deacetylase inhibitor romidepsin for adults with recurrent malignant glioma: North American Brain Tumor Consortium Study 03-03. Neuro Oncol. 2011May;13 5 509 16
204 - A Eramo, L Ricci-vitiani, A Zeuner, R Pallini, F Lotti, G Sette, et alChemotherapy resistance of glioblastoma stem cells. Cell Death Differ. 2006Jul;13 7 1238 41
205 - I. M Verma, M. D Weitzman, Gene therapy: twenty-first century medicine. Annu Rev Biochem. 2005 74 711 38
206 - K. M Kroeger, A. K Muhammad, G. J Baker, H Assi, M. K Wibowo, W Xiong, et alGene therapy and virotherapy: novel therapeutic approaches for brain tumors. Discov Med. 2010Oct;10 53 293 304
207 - M. G Castro, M Candolfi, K Kroeger, G. D King, J. F Curtin, K Yagiz, et alGene therapy and targeted toxins for glioma. Curr Gene Ther. 2011Jun;11 3 155 80
208 - M. S Lesniak, Gene therapy for malignant glioma. Expert Rev Neurother. 2006Apr;6 4 479 88
209 - F Colombo, L Barzon, E Franchin, M Pacenti, V Pinna, D Danieli, et alCombined HSV-TK/IL-2 gene therapy in patients with recurrent glioblastoma multiforme: biological and clinical results. Cancer Gene Ther. 2005Oct;12 10 835 48
210 - M Vanneman, G Dranoff, Combining immunotherapy and targeted therapies in cancer treatment. Nat Rev Cancer. 2012Apr;12 4 237 51
211 - R. L Yong, R. R Lonser, Immunotherapy trials for glioblastoma multiforme: promise and pitfalls. World Neurosurg. 2012May;77(5-6):636-8.
212 - L. M Liau, R. M Prins, S. M Kiertscher, S. K Odesa, T. J Kremen, A. J Giovannone, et alDendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment. Clin Cancer Res. 2005Aug 1;11 15 5515 25
213 - R Yamanaka, J Homma, N Yajima, N Tsuchiya, M Sano, T Kobayashi, et alClinical evaluation of dendritic cell vaccination for patients with recurrent glioma: results of a clinical phase I/II trial. Clin Cancer Res. 2005Jun 1;11 11 4160 7
214 - C Jackson, J Ruzevick, J Phallen, Z Belcaid, M Lim, Challenges in immunotherapy presented by the glioblastoma multiforme microenvironment. Clin Dev Immunol. 2011;2011